<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title> Histologic scoring indices for evaluation of disease activity in Crohn’s disease - Novak, G - 2017 | Cochrane Library</title> <meta content=" Histologic scoring indices for evaluation of disease activity in Crohn’s disease - Novak, G - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012351.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content=" Histologic scoring indices for evaluation of disease activity in Crohn’s disease - Novak, G - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012351.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012351.pub2" name="dc.identifier" scheme="DOI"/> <meta content=" Histologic scoring indices for evaluation of disease activity in Crohn’s disease" name="citation_title"/> <meta content="Gregor Novak" name="citation_author"/> <meta content="Claire E Parker" name="citation_author"/> <meta content="Robarts Clinical Trials" name="citation_author_institution"/> <meta content="Rish K Pai" name="citation_author"/> <meta content="Mayo Clinic" name="citation_author_institution"/> <meta content="John K MacDonald" name="citation_author"/> <meta content="Brian G Feagan" name="citation_author"/> <meta content="William J Sandborn" name="citation_author"/> <meta content="University of California San Diego" name="citation_author_institution"/> <meta content="Geert D'Haens" name="citation_author"/> <meta content="Vipul Jairath" name="citation_author"/> <meta content="Reena Khanna" name="citation_author"/> <meta content="reena.khanna@robartsinc.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD012351.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/07/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012351.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012351.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012351.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Biopsy; Colon [pathology]; Colonoscopy; Crohn Disease [*pathology]; Histological Techniques [methods, standards]; Ileum [pathology]; Prospective Studies; Rectum [pathology]; Reproducibility of Results; Retrospective Studies" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012351.pub2&amp;doi=10.1002/14651858.CD012351.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="WcPhDegp";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012351\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012351\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","pl","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012351.pub2",title:"\\n Histologic scoring indices for evaluation of disease activity in Crohn\\u2019s disease",firstPublishedDate:"Jul 21, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WcPhDegp&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012351.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012351.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012351.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012351.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012351.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012351.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012351.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012351.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012351.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012351.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4154 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012351.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-sec-0054"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-sec-0024"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-sec-0025"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-sec-0048"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/appendices#CD012351-sec-0057"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Methodology</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en"> Histologic scoring indices for evaluation of disease activity in Crohn’s disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/information#CD012351-cr-0002">Gregor Novak</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/information#CD012351-cr-0003">Claire E Parker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/information#CD012351-cr-0004">Rish K Pai</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/information#CD012351-cr-0005">John K MacDonald</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/information#CD012351-cr-0006">Brian G Feagan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/information#CD012351-cr-0007">William J Sandborn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/information#CD012351-cr-0008">Geert D'Haens</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/information#CD012351-cr-0009">Vipul Jairath</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012351.pub2/information#CD012351-cr-0010"><i class="icon corresponding-author fa fa-envelope"></i>Reena Khanna</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/information/en#CD012351-sec-0060">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 July 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012351.pub2">https://doi.org/10.1002/14651858.CD012351.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012351-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012351-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012351-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012351-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012351-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012351-abs-0001" lang="en"> <section id="CD012351-sec-0001"> <h3 class="title" id="CD012351-sec-0001">Background</h3> <p>Histologic assessment of mucosal disease activity has been increasingly used in clinical trials of treatment for Crohn's disease. However, the operating properties of the currently existing histologic scoring indices remain unclear. </p> </section> <section id="CD012351-sec-0002"> <h3 class="title" id="CD012351-sec-0002">Objectives</h3> <p>A systematic review was undertaken to evaluate the development and operating characteristics of available histologic disease activity indices in Crohn's disease. </p> </section> <section id="CD012351-sec-0003"> <h3 class="title" id="CD012351-sec-0003">Search methods</h3> <p>Electronic searches of MEDLINE, EMBASE, PubMed, and the Cochrane Library (CENTRAL) databases from inception to 20 July 2016 were supplemented by manual reviews of bibliographies and abstracts submitted to major gastroenterology meetings (Digestive Disease Week, United European Gastroenterology Week, European Crohn's and Colitis Organisation). </p> </section> <section id="CD012351-sec-0004"> <h3 class="title" id="CD012351-sec-0004">Selection criteria</h3> <p>Any study design (e.g. randomised controlled trial, cohort study, case series) that evaluated a histologic disease activity index in patients with Crohn’s disease was considered for inclusion. Study participants included adult patients (&gt; 16 years), diagnosed with Crohn’s disease using conventional clinical, radiographic or endoscopic criteria. </p> </section> <section id="CD012351-sec-0005"> <h3 class="title" id="CD012351-sec-0005">Data collection and analysis</h3> <p>Two authors independently reviewed the titles and abstracts of the studies identified from the literature search. The full text of potentially relevant citations were reviewed for inclusion and the study investigators were contacted as needed for clarification. Any disagreements regarding study eligibility were resolved by discussion and consensus with a third author. </p> <p>Two authors independently extracted and recorded data using a standard form. The following data were recorded from each eligible study: number of patients enrolled; number of patients per treatment arm; patient characteristics: age and gender distribution; description of histologic disease activity index utilized; and outcomes such as content validity, construct validity, criterion validity, responsiveness, intra‐rater reliability, inter‐rater reliability, and feasibility. </p> </section> <section id="CD012351-sec-0006"> <h3 class="title" id="CD012351-sec-0006">Main results</h3> <p>Sixteen reports of 14 studies describing 14 different numerical histological indices fulfilled the inclusion criteria. </p> <p>Inter‐rater reliability was assessed in one study. For the Naini and Cortina Score, estimates of correlation were 'almost perfect', ranging from r = 0.94 to 0.96. The methodological quality of this study with respect to reliability was 'good'. </p> <p>With respect to validity, correlation estimates between various histological scoring systems and Crohn's disease activity as measured by objective markers of inflammation (including C‐reactive protein, erythrocyte sedimentation rate, fecal calprotectin and fecal lactoferrin); endoscopic disease activity scores; clinical disease activity scores; and quality of life questionnaires were reported. Comparisons between histologic scoring indices and endoscopic scoring indices ranged from no correlation to 'substantial' (r = 0.779). The methodological quality of the studies that explored validity ranged form 'poor' to 'good'. </p> <p>Responsiveness data were available in seven studies. After subjects were administered a treatment of known efficacy, statistically significant change in the index score was demonstrated in five studies with respect to six indices. Two studies failed to indicate whether there was statistically significant change in the index score post‐treatment. With regard to methodological quality, six of the studies were rated as 'poor' and one of the studies was rated as 'fair'. </p> <p>Feasibility was assessed by one study. The Naini and Cortina Score was shown to be simple to use and feasible for every given case. </p> </section> <section id="CD012351-sec-0007"> <h3 class="title" id="CD012351-sec-0007">Authors' conclusions</h3> <p>Currently there is no fully validated histological scoring index for evaluation of Crohn's disease activity. Development of a validated histological scoring index for Crohn’s disease is a clinical and research priority. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012351-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012351-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012351-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012351-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012351-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012351-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012351-abs-0006">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012351-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012351-abs-0003" lang="en"> <h3>Histologic measurement tools for evaluation of disease activity in Crohn’s disease</h3> <p><b>What is Crohn's disease?</b> </p> <p>Crohn’s disease is a life‐long (chronic), inflammatory disease of the gastrointestinal tract characterized by abdominal pain (cramping), rectal bleeding, diarrhoea, weight loss, and tiredness. The disease has a changing course with periods of symptoms (called 'active' disease or relapse) and periods without symptoms (called 'remission'). </p> <p><b>What is a histological scoring index?</b> </p> <p>A histological scoring index measures disease activity based on the examination of biopsy specimens from the bowel (small pieces of tissue removed from the bowel) under a microscope. Biopsy specimens are removed from the bowel during colonoscopy (a non‐surgical procedure used to view the digestive tract using a camera) with biopsy forceps (instruments to grasp and remove pieces of tissue). Biopsies are then processed and assessed under microscope by a pathologist (a physician who interprets and diagnoses the changes caused by disease in tissues) who then rates disease activity using the index. </p> <p><b>What did the researchers investigate?</b> </p> <p>It is important that histological scoring indices measure what they are supposed to measure (validity); that they detect change after treatment (responsiveness); that the scores are consistently reproducible (reliability); and that they can be easily utilized (feasibility). The researchers investigated whether studies have assessed the validity, responsiveness, reliability and feasibility of histological scoring indices. </p> <p><b>What did the researcher find?</b> </p> <p>The researchers found that none of the existing histological scoring indices have been fully validated. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012351-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012351-sec-0054"></div> <h3 class="title" id="CD012351-sec-0055">Implication for methodological research</h3> <section id="CD012351-sec-0055"> <p>In summary, there are no currently available, fully‐validated histologic scoring indices for use in Crohn's disease patients. There is a great need for future studies to fully validate and assess operating properties of existing histological scoring indices, or to create indices according to the currently accepted standards for index development. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012351-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012351-sec-0022"></div> <p>Crohn's disease is a chronic, systemic disorder involving immune‐mediated inflammation of the gastrointestinal tract. While treatment goals have historically focused on achieving clinical remission, it is now understood that subclinical inflammation is capable of persisting in the absence of symptoms. Consequently, this inflammation can lead to progressive bowel damage and complications such as stricturing and penetrating disease (<a href="./references#CD012351-bbs2-0099" title="ArnottID , WattsD , GhoshS . Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn’s disease?. Alimentary Pharmacology and Therapeutics2002;16(5):857‐67. ">Arnott 2002</a>; <a href="./references#CD012351-bbs2-0105" title="HommesD , ColombelJF , EmeryP , GrecoM , SandbornWJ . Changing Crohn’s disease management: need for new goals and indices to prevent disability and improve quality of life. Journal of Crohn’s and Colitis2012;6:S224‐34. ">Hommes 2012</a>). With the advent of more potent therapies such as immunosuppressives and biologics, treatment aims have advanced beyond symptom resolution to healing of the involved intestinal mucosa (<a href="./references#CD012351-bbs2-0101" title="D’HaensGR , FedorakR , LémannM , FeaganBG , KammMA , CosnesJ , et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn’s disease. Inflammatory Bowel Diseases2009;15(10):1599‐604. ">D'Haens 2009</a>, <a href="./references#CD012351-bbs2-0100" title="BouguenG , LevesqueBG , FeaganBG , KavanaughA , Peyrin‐BirouletL , ColombelJF , et al. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clinical Gastroenterology and Hepatology2015; Vol. 13, issue 6:1042‐50. ">Bouguen 2013</a>). However, the degree of mucosal healing necessary to prevent future complications from progressive bowel damage has yet to be defined. Previous research has established that the presence of endoscopic healing does not necessarily correlate with an absence of histologic inflammation, as up to one‐third of biopsies from patients with Crohn’s disease with endoscopically healed mucosa demonstrate evidence of ongoing histologic disease (<a href="./references#CD012351-bbs2-0107" title="KorelitzBI , SommersSC . Response to drug therapy in Crohn's disease: evaluation by rectal biopsy and mucosal cell counts. Journal of Clinical Gastroenterology1984;6(2):123‐8. ">Korelitz 1984</a>; <a href="./references#CD012351-bbs2-0111" title="MolanderP , SipponenT , KemppainenH , JussilaA , BlomsterT , KoskelaR , et al. Achievement of deep remission during scheduled maintenance therapy with TNF α‐blocking agents in IBD. Journal of Crohn's and Colitis2013;7(9):730‐5. ">Molander 2013</a>). </p> <p>In order to evaluate the benefit of histologic mucosal healing as a treatment target in clinical trials, a scoring index is necessary to objectively quantify the degree of histologic inflammation. The development of such a validated index in Crohn's disease is challenging for several reasons. Not only does the potential exist for endoscopic biopsy sampling error due to the segmental, transmural nature of intestinal inflammation in Crohn's disease, but additionally, limited data exist regarding which histologic features are most relevant for assessing active inflammation in Crohn's disease (<a href="./references#CD012351-bbs2-0110" title="MojtahedA , KhannaR , SandbornWJ , DʼHaensGR , FeaganBG , ShackeltonLM , et al. Assessment of histologic disease activity in Crohn's disease: a systematic review. Inflamm Bowel Diseases2014;20(11):2092‐103. ">Mojtahed 2014</a>). As such, the operating properties of the index must be rigorously demonstrated before it can be recommended for use in clinical trials. These operating properties include validity (the extent to which an instrument truly measures the outcome that it is intended to assess), responsiveness (the ability to detect a meaningful change in health status), reliability (the consistency or reproducibility of an instrument), and feasibility (the ease with which an instrument can be utilized in a given setting) (<a href="./references#CD012351-bbs2-0106" title="KirshnerB , GuyattG . A methodological framework for assessing health indices. Journal of Chronic Diseases1985;38(1):27‐36. ">Kirshner 1985</a>). </p> <p>The first histologic disease activity index used in clinical trials for inflammatory bowel disease was the Truelove and Richards' Index which was developed for ulcerative colitis in 1956 (<a href="./references#CD012351-bbs2-0113" title="TrueloveSC , RichardsWC . Biopsy studies in ulcerative colitis. British Medical Journal1956;1:1315‐18. ">Truelove 1956</a>). Since then, several Crohn's disease‐specific histologic indices have been described, which are broadly categorized as either stepwise or numerical. Stepwise instruments separate disease activity into categories such as mild, moderate, and severe. Numerical instruments assign a point scale to individual biopsy findings which can then be summed to determine an overall score (<a href="./references#CD012351-bbs2-0110" title="MojtahedA , KhannaR , SandbornWJ , DʼHaensGR , FeaganBG , ShackeltonLM , et al. Assessment of histologic disease activity in Crohn's disease: a systematic review. Inflamm Bowel Diseases2014;20(11):2092‐103. ">Mojtahed 2014</a>). </p> <p>The features assessed for each biopsy specimen vary according to the histologic disease activity index. Examples of such features include acute and chronic inflammatory cell infiltrates, epithelial damage, crypt distortion, and the presence of granulomas, as well as the location from which the biopsy was collected. For example, the index developed by Ward and Webb in 1977 is based exclusively on rectal biopsies in Crohn's patients (<a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a>), as compared to the instrument utilized by <a href="./references#CD012351-bbs2-0035" title="ColombelJF , SolemCA , SandbornWJ , BooyaF , LoftusEVJr , HarmsenWS , et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut2006;55:1561‐7. ">Colombel 2006</a> which is limited to ileal biopsies. The more widely used Global Histologic Disease Activity Score (GHAS) (<a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>), and the Naini and Cortina Score (<a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a>), are numerical instruments which allow for separate grading of both ileal and colonic specimens. </p> <p>With such variation among the histologic indices for Crohn's disease, the operating properties of these instruments require evaluation to identify the most reliable and accurate index for measuring histologic disease activity. </p> <section id="CD012351-sec-0023"> <h3 class="title" id="CD012351-sec-0023">Why it is important to do this review</h3> <p>There are limited data available on the operating properties of indices used for the evaluation of histologic activity in Crohn's disease. This review examines the relative merits of each available index and identifies areas where further research is needed to develop an optimal evaluative instrument for use in clinical trials. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012351-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012351-sec-0024"></div> <p>The primary objective was to systematically review the current literature describing the development and operating characteristics of available histologic disease activity indices in Crohn’s disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012351-sec-0025" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012351-sec-0025"></div> <section id="CD012351-sec-0026"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012351-sec-0027"> <h4 class="title">Types of studies</h4> <p>Any study design (e.g. randomised controlled trial, cohort study, case series) that evaluates a histologic disease activity index in patients with Crohn’s disease was considered for inclusion. Study subjects included adult patients (&gt; 16 years), diagnosed with Crohn's disease using conventional clinical, radiographic, or endoscopic criteria. </p> </section> <section id="CD012351-sec-0028"> <h4 class="title">Types of data</h4> <p>Histologic scoring data obtained from eligible studies were considered for inclusion.</p> </section> <section id="CD012351-sec-0029"> <h4 class="title">Types of methods</h4> <p>The methods used to construct and validate the histologic disease activity index (e.g. validity, responsiveness, reliability and feasibility) were examined in detail and described for each included study. The number of pathologists who scored the histologic index in each study was also reported, in addition to information on whether the pathologists were blinded from the other raters' scores and the participants' clinical and endoscopic disease severity. </p> </section> <section id="CD012351-sec-0030"> <h4 class="title">Types of outcome measures</h4> <p><b>Reliability:</b> Measures of reliability (intra‐rater reliability, inter‐rater reliability, test‐retest reliability, or internal consistency) were assessed by evaluating correlation estimates, as expressed by the interclass correlation coefficient (ICC), kappa statistic or Pearson's r. </p> <p><b>Validity</b>: Each study was assessed to determine whether validity was measured, which is broadly defined as evidence that variations in Crohn’s disease activity causally produce variations in the index measurement outcomes. Studies were reviewed for evidence of content validity, criterion validity, and construct validity for available histologic disease activity scores. </p> <p>Content validation refers to a demonstration that the elements of the histology scoring index are sufficient to measure disease activity in Crohn’s disease. Content validity is generally based on qualitative assessment. For example, evidence of content validity may include an expert panel opinion on the relevant components to include in an index, or a systematic review of the literature supporting index development. </p> <p>Criterion validity refers to the degree to which index scores adequately reflect true Crohn’s disease activity as compared to gold standard measurements of disease activity. Unfortunately, the lack of a single gold standard for measuring Crohn’s disease activity is a limitation of these assessments. Studies of predictive criterion validity which compare whether the score predicts true Crohn's disease activity as measured by objective measures of inflammation including C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), fecal calprotectin and fecal lactoferrin or sequelae in the future, such as surgery or disability were reported. Statistical parameters reported for agreement between the histologic index and disease gold standards were assessed (i.e. sensitivity, specificity, receiver operating characteristic (ROC) curve, area under the curve, mean difference, weighted kappa, Spearman’s r squared, and the ICC). </p> <p>Construct validation acknowledges the lack of a gold standard measurement for Crohn's disease activity, and instead assesses whether the index is consistent with other available markers of disease activity. Studies of the construct validity of a histologic index were reported if the correlation between the histologic index score and endoscopic disease activity indices; or the correlation between histologic score and clinical disease activity indices (e.g. Crohn's Disease Activity Index (CDAI)); or the correlation between histologic score and quality of life measures were reported. The minimal clinically important difference and appropriate cut‐off values to determine active and inactive disease states, clinical response and clinical remission were examined. </p> <p><b>Responsiveness:</b> Changes in the histologic disease activity scores following a treatment of known efficacy served as an assessment of responsiveness, and the ability of an index to detect change. Responsiveness was quantified using indicators of effect size or its functions (<a href="./references#CD012351-bbs2-0114" title="ZouGY . Quantifying responsiveness of quality of life measures without an external criterion. Quality of Life Research2005;14(6):1545‐52. ">Zou 2005</a>), or the use of ROC curves to describe how well various score changes can be used to distinguish between improved and unimproved patients (<a href="./references#CD012351-bbs2-0102" title="DeyoRA , DiehrP , PatrickDL . Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Controlled Clinical Trials1991;12(4):142S‐58S. ">Deyo 1991</a>). </p> <p><b>Feasibility:</b> Feasibility was assessed as rater evaluation of the ease of index administration and the time required for scoring. </p> <p>The criteria proposed by Landis and Koch was used to interpret correlation estimates. A correlation estimate of less than 0.2 was considered 'slight', 0.21 to 0.40 was considered 'fair', 0.41 to 0.60 was considered 'moderate', 0.61 to 0.80 was considered 'substantial' and 0.81 to 1.00 was considered 'almost perfect' (<a href="./references#CD012351-bbs2-0108" title="LandisJR , KochGG . The measurement of observer agreement for categorical data. Biometrics1977;33(1):159–74. ">Landis 1977</a>). </p> </section> </section> <section id="CD012351-sec-0031"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012351-sec-0032"> <h4 class="title">Electronic searches</h4> <p>A computer aided search to identify applicable studies was conducted using the following databases: MEDLINE (Ovid), EMBASE (Ovid), PubMed, and the Cochrane Library (CENTRAL) from inception to 20 July 2016. No language or document type restrictions were applied. The search strategies are listed in <a href="./appendices#CD012351-sec-0058">Appendix 1</a>. </p> </section> <section id="CD012351-sec-0033"> <h4 class="title">Searching other resources</h4> <p>We performed a manual review of bibliographies and abstracts submitted to major gastroenterology meetings (2000 to July 2016) including: </p> <p>1. Digestive Disease Week;</p> <p>2. United European Gastroenterology Week; and</p> <p>3. European Crohn's and Colitis Organisation.</p> <p>Reference lists from retrieved articles were scanned to identify additional citations that may have been overlooked by the database search. </p> </section> </section> <section id="CD012351-sec-0034"> <h3 class="title" id="CD012351-sec-0034">Data collection and analysis</h3> <section id="CD012351-sec-0035"> <h4 class="title">Selection of studies</h4> <p>Two authors (GN, CEP) independently reviewed the titles and abstracts of the studies identified from the literature search. The full text of potentially relevant citations were reviewed for inclusion and study investigators were contacted as needed for clarification. Case reports, editorials, commentary, letters to the editor and meeting reports were excluded. Potentially relevant publications were translated into English if necessary. Any disagreements regarding study eligibility were resolved by discussion and consensus with a third author (JKM). </p> <p>A standardized form was used to assess eligibility of trials for inclusion in the study. Each item on the form was scored as yes, no or unclear. The following items were assessed: </p> <p>a) Diagnosis of Crohn’s disease; and</p> <p>b) Use of a histologic disease activity index; and</p> <p>c) Evaluation of validity, responsiveness, reliability, and feasibility of histologic disease activity index. </p> </section> <section id="CD012351-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>A standardized form was used to extract information from selected studies. Two authors (GN, CEP) independently extracted and recorded data. The following data was recorded from each eligible study: </p> <p>a) Number of patients enrolled, number of patients per treatment arm;</p> <p>b) Patient characteristics: age and gender distribution;</p> <p>c) Description of histologic disease activity index utilized; and</p> <p>d) Outcomes: validity, content validity, construct validity, criterion validity, responsiveness, intra‐rater reliability, inter‐rater reliability, and feasibility. </p> </section> <section id="CD012351-sec-0037"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the following criteria to appraise the risk of bias of included studies:</p> <p> <ul id="CD012351-list-0001"> <li> <p>Blinding to clinical and endoscopic information; and</p> </li> </ul> <ul id="CD012351-list-0002"> <li> <p>Independent observation by histopathologists.</p> </li> </ul> </p> <p>Blinding to clinical information such as symptoms, physical examination or laboratory information, and endoscopic information, is necessary to objectively assess histologic data. Furthermore, independent observation is essential to ensure that we are confident in the inter‐rater reliability coefficients. </p> <p>We also assessed the methodology quality of the included studies using the COSMIN (COnsensus‐based Standards for the selection of health Measurement INstruments) checklist. The checklist consists of 10 properties: (A) internal consistency, (B) reliability, (C) measurement error, (D) content validity, (E) structural validity (factor analysis), (F) hypothesis testing, (G) cross‐cultural validity, (H) criterion validity, (I) responsiveness to change and (J) interpretability. Each property is rated on a four‐point scale (1 = poor, 2 = fair, 3 = good, or 4 = excellent). The overall score for the assessment of an individual measurement property is obtained by taking the lowest score for any of the items in the box (i.e. if any item in the box is scored as 'poor' then the overall score for that property is 'poor'). Generalisability was also be assessed as part of the COSMIN checklist. </p> </section> <section id="CD012351-sec-0038"> <h4 class="title">Measures of the effect of the methods</h4> <p>Descriptive statistics were used to report the validation of outcome data. Frequencies and percentages were shown for categorical variables. </p> </section> <section id="CD012351-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>Where possible, authors were contacted to provide any missing information.</p> </section> <section id="CD012351-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>Given that this was a descriptive review, we did not conduct sensitivity analyses that excluded: (1) unpublished studies; and (2) studies of low methodological quality. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012351-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012351-sec-0041"></div> <section id="CD012351-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD012351-sec-0043"> <h4 class="title">Results of the search</h4> <p>The literature search conducted on 20 July 2016 identified 3520 records. Four additional records were identified through other sources. After 951 duplicates were removed, a total of 2573 records were screened for inclusion. Of these, 102 reports were selected for full text review. Eighty‐six reports of 84 studies were excluded (see <a href="./references#CD012351-sec-0064" title="">Characteristics of excluded studies</a>), leaving 16 reports of 14 studies evaluating numerical histological scores that met the pre‐defined inclusion criteria (<a href="#CD012351-fig-0001">Figure 1</a>). During the review process, we identified multiple overlapping stepwise histologic disease activity indices with the same or similar items. The index development process involves assessment of individual items. In our review, all of items of the stepwise histological disease activity indices from excluded studies were included among the items of numerical HDAI of the included studies. We decided to exclude all stepwise indices from further analysis. </p> <div class="figure" id="CD012351-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012351-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012351.pub2/media/CDSR/CD012351/image_n/nCD012351-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012351-sec-0044"> <h4 class="title">Included studies</h4> <p>Sixteen reports of 14 studies reported data on the operating characteristics of numerical histological indices (<a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a>; <a href="./references#CD012351-bbs2-0002" title="BaertF J , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22‐8. ">Baert 1999</a>; <a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a>; <a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a>; <a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a>; <a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a>; <a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a>; <a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a>; <a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a>; <a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a>; <a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a>; <a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a>; <a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a>). In total, 13 different numerical histologic indices were identified. These histologic indices included the Agnholt Score, the Global Histological Activity Score (GHAS), Drews Score, Colonic and Ileal Global Histological Activity Score, Gomes Score, Laherie Score, Average Histologic Score, Naini and Cortina Score, Regueiro Score, Sipponen Score, Dieleman Score, Ward Score and Saverymuttu Score. Six of these scores (the Agnholt Score, Colonic and Ileal Global Histological Activity Score, Laherie Score, Average Histologic Score, Regueiro Score and Sipponen Score) are modifications of the GHAS index (<a href="#CD012351-tbl-0001">Table 1</a>). The scoring index cut‐offs of the histologic scoring indices that have undergone validation testing are listed in <a href="#CD012351-tbl-0002">Table 2</a>. </p> <div class="table" id="CD012351-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Indices that have been fully or partially validated</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Histologic index evaluated</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>GHAS or modification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agnholt Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global Histological Activity Score (GHAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drews Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonic Global Histological Activity Score (CGHAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileal Global Histological Activity Score (IGHAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gomes Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laharie Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Average Histologic Score (AHS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naini and Cortina Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regueiro Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sipponen Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dieleman Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ward Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Savermuttu Index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD012351-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Scoring Index Cut‐offs</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cut‐off</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agnholt Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic inflammatory activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0002" title="BaertF J , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22‐8. ">Baert 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GHAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GHAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drews Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic inflammatory activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stage 0 (score 0): no increase in inflammation</p> <p>stage 1 (1‐3): chronic, non‐active inflammation</p> <p>stage 2 (4‐6): mild active inflammation</p> <p>stage 3 (7‐9): moderate active inflammation</p> <p>stage 4 (10‐14): severe active inflammation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gobes Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gomes Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported. Maximum score: 24.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laharie Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported. Score ranges from 1 (no activity) to 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AHS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naini and Cortina Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>likelihood of IBD/</p> <p>histopathologic</p> <p>support for IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Probability of chronic ileitis (max. score = 10)</p> <p>low 0‐2</p> <p>moderate 3‐4</p> <p>high 5‐10</p> <p>Probability of chronic colitis (max. score =17)</p> <p>low 0‐3</p> <p>moderate 4‐8</p> <p>high 9‐17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regueiro Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>inactive: 0</p> <p>mildly active: 1‐5</p> <p>moderately active: 6‐10</p> <p>severely active: 11‐14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sipponen Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dieleman Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic inflammatory activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ward Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prognosis of Crohn's disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported. Maximum score 10.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saverymuttu Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total score of 4 items:</p> <p>0‐1 ‐ Grade 0 (none inflammation)</p> <p>2‐4 ‐ Grade 1 (mild inflammation)</p> <p>5‐8 ‐ Grade 2 (moderate inflammation)</p> <p>9‐12 ‐ Grade 3 (severe inflammation)</p> <p>Histologic healing was defined as grade of 0</p> <p>Histologic improvement (including healing).was defined</p> <p>as a decrease of at least 1 grade</p> </td> </tr> </tbody> </table> </div> <p><b>Setting</b> </p> <p>Eleven studies were prospective (<a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a>; <a href="./references#CD012351-bbs2-0002" title="BaertF J , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22‐8. ">Baert 1999</a>; <a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a>; <a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a>; <a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a>; <a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a>; <a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a>; <a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a>; <a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a>; <a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a>), two studies were retrospective (<a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a>; <a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a>) and one study was composed of two retrospective phases (calibration and validation), followed by a prospective application phase (<a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a>). </p> <p>Histologic assessment was performed by a single pathologist in ten studies (<a href="./references#CD012351-bbs2-0002" title="BaertF J , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22‐8. ">Baert 1999</a>; <a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a>; <a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a>; <a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a>; <a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a>; <a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a>; <a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a>; <a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a>; <a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a>), and by two pathologists in two studies (<a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a>; <a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a>). <a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a> and <a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a> did not report how the histologic assessments were performed. </p> <p><b>Description of included histologic scoring indices</b> </p> <p>One study specifically aimed to develop and assess the operating characteristics of a histologic scoring index. <a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a> described the development of the Naini and Cortina Score in a multi‐phase study. The score was initially intended to standardize and reduce interpretive variability in histopathological assessment of mucosal biopsies for chronic ileocolitis and inflammatory bowel disease (IBD) diagnosis. The Naini and Cortina Score consists of 15 items which allows for separate scoring of the colon (ten items) and ileum (five items). For each item, scores range from zero to two. The score was developed in three phases. In phase one (calibration), the authors developed a histologic scoring index for chronic ileocolitis, measured agreement between two pathologists, and determined the ability of the score to distinguish ileocolitis from negative biopsies using retrospective specimens from ten patients. In phase two (validation phase), the investigators retrospectively included 164 patients who had undergone colonoscopy with biopsy procurement for clinical suspicion of ileocolitis to reaffirm agreement between pathologists, confirm the hypothesis that IBD cases would score high on the index, and to determine the likelihood of IBD. In phase three (application phase), the pathologists prospectively confirmed the accuracy and ease of application of the score in 30 patients. </p> <p>Other included studies did not specifically aim to assess the operating properties of a histologic scoring index, but included some degree of validation testing. Furthermore, the construction and design of histological indices is not well reported. This could be due to word count limitations in articles. </p> <p>In 1977, the first numerical histologic scoring index for Crohn's disease was described, which assessed the correlation between histology of rectal biopsies and prognosis (<a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a>). The Ward Score consists of ten histologic features divided into two groups: first, non‐graded features which can be rated as either present or absent (e.g. ulceration, fissures), and, second, graded features which can be scored on a semi‐quantitative scale (e.g. infiltration of neutrophils). The total score is calculated by adding the scores of individual features with a maximum value of ten. The Ward Score is based exclusively on rectal biopsies which means that it is not applicable in patients with involvement of the colon, small intestine or upper‐gastrointestinal tract. This score has not been used widely in clinical trials. </p> <p>The most commonly used histologic disease activity index in clinical studies is the GHAS. In the initial index development study, ileal fecal fluids were infused into the neoterminal ileum of patients with a temporary diverting ileostomy. Biopsies from the ileum and colon were evaluated to determine whether the fecal stream causes recurrence of inflammation after surgery in the ileum (<a href="./references#CD012351-bbs2-0038" title="D'HaensGR , GeboesK , PeetersM , BaertF , PenninckxF , RutgeertsP . Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology1998;114:262‐7. ">D'Haens 1998</a>). The GHAS consists of eight items assessing acute and chronic inflammatory changes, epithelial damage and the extent of inflammation (i.e. the proportion of biopsy specimens affected). Each of the eight items is scored, with the totals subsequently added together (<a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>). The GHAS has been used in multiple studies, but only <a href="./references#CD012351-bbs2-0002" title="BaertF J , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22‐8. ">Baert 1999</a> and <a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> have evaluated the operating properties of this index. </p> <p>Many modifications of the GHAS have been proposed, and seven of these modifications have undergone validation testing. Geboes assessed the GHAS separately in the colon (CGHAS) and ileum (IGHAS) (<a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a>). Similarly, <a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a> counted ileal and colonic scores separately but colonic histologic activity was the sum of the total scores for four segments (right, transverse and left colon, and rectum). Thus, the maximum score for the ileum and colon was 16 and 64, respectively. For the Average Histology Score (AHS), the histologic disease activity of each explored colonic segment (rectum and sigmoid colon, descending colon, transverse colon, ascending colon, and cecum) and terminal ileum is scored with the GHAS. The final AHS is achieved by dividing the sum of individual intestinal segmental scores by the number of intestinal segments explored (<a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a>). Agnholt developed an index that includes only inflammatory changes from the GHAS (i.e. epithelial damage, mononuclear cells in lamina propria, polymorphonuclear cells in lamina propria and neutrophils in the epithelium). The final score is an average score of the individual biopsies (<a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a>). The modification of the GHAS by <a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a> omits the last item from the original GHAS (number of biopsy specimens affected), with total scores ranging from one to thirteen. Similarly, Regueiro replaced the 'number of biopsy specimens affected' item with 'pyloric gland metaplasia'. The maximum score of this histologic index, which focuses on the biopsies from the neoterminal ileum, is 14 (<a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a>). </p> <p>The second most commonly used histologic activity index in Crohn's disease was first described by <a href="./references#CD012351-bbs2-0081" title="SaverymuttuSH , CamilleriM , ReesH . Indium 111‐granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal Indium 111‐granulocyte excretion. Gastroenterology1986;90:1121‐8. ">Saverymuttu 1986</a>. This numerical score was initially used to compare histologic disease activity to indium 111‐granulocyte scanning. Each biopsy specimen was assessed for the severity of changes in enterocytes and crypts, and for lamina propria involvement by mononuclear cells and neutrophils. These four items are scored on a scale from zero to three, depending on the severity of abnormalities, and added together. The average score from individual biopsy specimens from each region is converted to a grade (grade zero to three) with higher grades indicating greater disease activity (<a href="./references#CD012351-bbs2-0081" title="SaverymuttuSH , CamilleriM , ReesH . Indium 111‐granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal Indium 111‐granulocyte excretion. Gastroenterology1986;90:1121‐8. ">Saverymuttu 1986</a>). This scoring system has been applied in multiple studies, and one study has reported on the operating characteristics of the Saverymuttu Score (<a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a>). </p> <p>First described in a mouse study, the Dieleman Score assesses histologic disease activity based on the amount of inflammation (zero to three), depth of inflammation (zero to three), amount of crypt damage (zero to four) and crypt regeneration (zero to four). These changes are also quantified as a percentage of involvement on a scale from zero to four (<a href="./references#CD012351-bbs2-0103" title="DielemanLA , PalmenMJ , AkolH , BloemenaE , PeñaAS , MeuwissenSG , et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clinical and Experimental Immunology1998;114(3):385‐91. ">Dieleman 1998</a>). This histologic scoring index was subsequently applied and partially validated in a trial evaluating the opioid antagonist naltrexone in active Crohn's disease (<a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a>). </p> <p>One of the included studies validated a histologic score that is both numerical and stepwise. The Gomes Score is achieved by adding stepwise scores that are graded on a scale of zero (normal) to four (most severe inflammation with active ulcerations) from individual biopsies taken from six colonic segments for a maximum total of 24 (<a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a>). Reminiscent of the Ward Score, this index is based exclusively on colonic biopsies thus limiting its use in Crohn's disease patients. </p> <p>The Drews Score is based exclusively on ileal biopsies. It was developed in a study comparing histology to sonographically measured bowel wall vascularity and clinical disease activity (<a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a>). Pathomorphological features of the score include infiltration by lymphocytes and plasma cells in the chronic inactive disease stage, infiltration of granulocytes in the active phase, crypt deformations, erosions and abscesses, and epithelioid cell granulomas. Histologic severity is ranked on a scale from zero to four. </p> </section> <section id="CD012351-sec-0045"> <h4 class="title">Excluded studies</h4> <p>Eighty‐six reports of 84 studies were excluded with reasons (see <a href="./references#CD012351-sec-0064" title="">Characteristics of excluded studies</a>). </p> <p>Among the excluded reports we identified 53 different histologic scoring indices. Fifty studies (52 reports) described 41 stepwise instruments (<a href="./references#CD012351-bbs2-0016" title="AjajWM , LauensteinTC , PelsterG , GerkenG , RuehmSG , DebatinJF , et al. Magnetic resonance colonography for the detection of inflammatory diseases of the large bowel: quantifying the inflammatory activity. Gut2005;54(2):257‐63. ">Ajaj 2005</a>; <a href="./references#CD012351-bbs2-0017" title="AllgayerH , RoischU , ZehnterE , ZiegenhagenDJ , DienesHP , KruisW . Colonic ornithine decarboxylase in inflammatory bowel disease: ileorectal activity gradient, guanosine triphosphate stimulation, and association with epithelial regeneration but not the degree of inflammation and clinical features. Digestive Diseases and Sciences2007;52(1):25‐30. ">Allgayer 2007</a>; <a href="./references#CD012351-bbs2-0018" title="AllisonMC , CornwallS , PoulterLW , DhillonAP , PounderRE . Macrophage heterogeneity in normal colonic mucosa and in inflammatory bowel disease. Gut1988;29:1531‐8. ">Allison 1988</a>; <a href="./references#CD012351-bbs2-0020" title="BaarsJE , VogelaarL , WolfhagenFH , BiermannK , KuipersEJ , van derWoudeCJ . A short course of corticosteroids prior to surveillance colonoscopy to decrease mucosal inflammation in inflammatory bowel disease patients: Results from a randomized controlled trial. Journal of Crohn's and Colitis2010;4(6):661‐8. ">Baars 2010</a>; <a href="./references#CD012351-bbs2-0021" title="BaarsJE , NuijVJ , OldenburgB , KuipersEJ , Van DerWoudeCJ . The majority of patients with inflammatory bowel disease in clinical remission has mucosal inflammation. Gastroenterology2011;1:S776. BaarsJE , NuijVJ , OldenburgB , KuipersEJ , van derWoudeCJ . Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflammatory Bowel Diseases2012;18(9):1634‐40. ">Baars 2012</a>; <a href="./references#CD012351-bbs2-0023" title="BeattieRM , SchiffrinEJ , Donnet‐HughesA , HuggettAC , DomizioP , MacDonaldTT , et al. Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease. Alimentary Pharmacology and Therapeutics1994;8(6):609‐15. ">Beattie 1994</a>; <a href="./references#CD012351-bbs2-0024" title="BergeronV , Nion‐LarmurierI , VienneA , SeksikP , SokolH , Ruskone‐FourmestrauxA , et al. Azathioprine (AZA) is associated with less histological inflammation of the colon in clinically inactive IBD. Gastroenterology2010;1:S693. ">Bergeron 2010</a>; <a href="./references#CD012351-bbs2-0027" title="BinderV . A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa, and cytologic picture of mucosal exudate in ulcerative colitis. Scandinavian Journal of Gastroenterology1970;5:627‐32. ">Binder 1970</a>; <a href="./references#CD012351-bbs2-0028" title="BojicD , BojicB , ProticM , SvorcanP , GligorijevicV , NecicD , et al. Fecal calprotectin is reliable surrogate marker of endoscopic and histologic mucosal healing in Crohn's disease and ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S34. ">Bojic 2011</a>; <a href="./references#CD012351-bbs2-0030" title="BreeseEJ , MichieCA , NichollsSW , WilliamsCB , DomizioP , Walker‐SmithJA , et al. The effect of treatment on lymphokine‐secreting cells in the intestinal mucosa of children with Crohn's disease. Alimentary Pharmacology and Therapeutics1995;9:547‐52. ">Breese 1995</a>; <a href="./references#CD012351-bbs2-0032" title="ChioreanMV , SandrasegaranK , SaxenaR , MaglinteDD , NakeebA , JohnsonCS . Correlation of CT enteroclysis with surgical pathology in Crohn's disease. American Journal of Gastroenterology2007;102(11):2541‐50. ">Chiorean 2007</a>; <a href="./references#CD012351-bbs2-0033" title="Chung‐FayeG , SandhuK , LoganRP , SherwoodRA . Fecal calproctectin is strongly predictive of clinical disease activity and histological severity in inflammatory bowel disease. Gastroenterology2011;1:S421. ">Chung‐Faye 2011</a>; <a href="./references#CD012351-bbs2-0034" title="Chung‐FayeG , RahmanA , SandhuK , HayeeB , TumovaJ , SherwoodR . Fecal calprotectin is an accurate predictor of endoscopic and histological disease activity in IBD. Journal of Crohn's and Colitis2014;8:S153‐4. ">Chung‐Faye 2014</a>; <a href="./references#CD012351-bbs2-0035" title="ColombelJF , SolemCA , SandbornWJ , BooyaF , LoftusEVJr , HarmsenWS , et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut2006;55:1561‐7. ">Colombel 2006</a>; <a href="./references#CD012351-bbs2-0036" title="CosinJ , Ortiz‐MasiaD , QuintanaE , CabreroM , CalatayudS , NicolauMJ , et al. Histological damage correlates with the number of HIF‐2 positive cells in the lamina propria of patients with inflammatory bowel disease. Basic and Clinical Pharmacology and Toxicology2011;109:21. ">Cosin 2011</a>; <a href="./references#CD012351-bbs2-0041" title="DiSabatinoA , Saarialho‐KereU , BuckleyMG , GordonJN , BiancheriP , RovedattiL , et al. Stromelysin‐1 and macrophage metalloelastase expression in the intestinal mucosa of Crohn's disease patients treated with infliximab. European Journal of Gastroenterology and Hepatology2009;21(9):1049‐55. ">Di Sabatino 2009</a>; <a href="./references#CD012351-bbs2-0040" title="DieckgraefeBK , CrimminsDL , LandtV , HouchenC , AnantS , Porche‐SorbetR , et al. Expression of the regenerating gene family in inflammatory bowel disease mucosa: Reg Ialpha upregulation, processing, and antiapoptotic activity. Journal of Investigative Medicine2002;50(6):421‐34. ">Dieckgraefe 2002</a>; <a href="./references#CD012351-bbs2-0042" title="EllrichmannM , BethgeJ , NikolausS , ArltA , KuehbacherT , SchreiberS , et al. Endoscopic ultrasound of the colon can differentiate between crohn's disease and ulcerative colitis and reliably quantifies the degree of inflammation ‐ A prospective, blinded, and controlled comparative study. Gastrointestinal Endoscopy2012;1:AB444. EllrichmannM , Wietzke‐BraunP , DharS , NikolausS , ArltA , BethgeJ , et al. Endoscopic ultrasound of the colon for the differentiation of Crohn's disease and ulcerative colitis in comparison with healthy controls. Alimentary Pharmacology and Therapeutics2014;39(8):823‐33. ">Ellrichmann 2012</a>; <a href="./references#CD012351-bbs2-0043" title="EweK , BottgerT , BuhrHJ , EckerKW , OttoHF . Low‐dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo‐controlled trial. German Budesonide Study Group. European Journal of Gastroenterology and Hepatology1999;11(3):277‐82. ">Ewe 1999</a>; <a href="./references#CD012351-bbs2-0044" title="FazioVW , MarchettiF , ChurchM , GoldblumJR , LaveryC , HullTL , et al. Effect of resection margins on the recurrence of Crohn's disease in the small bowel. A randomized controlled trial. Annals of Surgery1996;224(4):563‐71. ">Fazio 1996</a>; <a href="./references#CD012351-bbs2-0045" title="FerranteM , deHertoghG , HlavatyT , D'HaensG , PenninckxF , D'HooreA , et al. The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence. Gastroenterology2006;130(6):1595‐606. ">Ferrante 2006</a>; <a href="./references#CD012351-bbs2-0048" title="GrigaT , VoigtE , GretzerB , BraschF , MayB . Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease. Hepatogastroenterology1999;46(26):920‐3. ">Griga 1999</a>; <a href="./references#CD012351-bbs2-0049" title="HaberHP , BuschA , ZiebachR , DetteS , RuckP , SternM . Ultrasonographic findings correspond to clinical, endoscopic, and histologic findings in inflammatory bowel disease and other enterocolitides. Journal of Ultrasound in Medicine2002;21(4):375‐82. ">Haber 2002</a>; <a href="./references#CD012351-bbs2-0050" title="HanskiC , BornM , FossHD , MarowskiB , MansmannU , ArastehK , et al. Defective post‐transcriptional processing of MUC2 mucin in ulcerative colitis and in Crohn's disease increases detectability of the MUC2 protein core. Journal of Pathology1999;188(3):304‐11. ">Hanski 1999</a>; <a href="./references#CD012351-bbs2-0054" title="KaiserT , LanghorstJ , WittkowskiH , BeckerK , FriedrichA W , RuefferA , et al. Faecal S100A12 as a non‐invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut2007;56(12):1706‐13. ">Kaiser 2007</a>; <a href="./references#CD012351-bbs2-0055" title="KolkmanJJ , FalkeTH , RoosJC , VanDijkDH , BanninkIM , DenHollanderW , et al. Computed tomography and granulocyte scintigraphy in active inflammatory bowel disease. Comparison with endoscopy and operative findings. Digestive Diseases and Sciences1996;41(4):641‐50. ">Kolkman 1996</a>; <a href="./references#CD012351-bbs2-0056" title="KoutroubakisIE , KoukourakiSI , DimouliosPD , VelidakiAA , KarkavitsasNS , KouroumalisEA . Active inflammatory bowel disease: evaluation with 99mTc (V) DMSA scintigraphy. Radiology2003;229(1):70‐4. ">Koutroubakis 2003</a>; <a href="./references#CD012351-bbs2-0057" title="KozarekRA , PattersonDJ , GelfandMD , BotomanVA , BallTJ , WilskeKR . Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Annals of Internal Medicine1989;110:353‐6. ">Kozarek 1989</a>; <a href="./references#CD012351-bbs2-0059" title="LasockiA , PitmanA , WilliamsR , LuiB , KaladeA V , FarishS . Relative efficacy of different MRI signs in diagnosing active Crohn's disease, compared against a histological gold standard. Journal of Medical Imaging and Radiation Oncology2011;55(1):11‐9. ">Lasocki 2011</a>; <a href="./references#CD012351-bbs2-0060" title="LeddinDJ , PatersonWG , DaCostaLR , DindaPK , DepewWT , MarkotichJ , et al. Indium‐111‐labeled autologous leukocyte imaging and fecal excretion. Comparison with conventional methods of assessment of inflammatory bowel disease. Digestive Diseases and Sciences1987;32(4):377‐87. ">Leddin 1987</a>; <a href="./references#CD012351-bbs2-0061" title="LenzeF , WesslingJ , BremerJ , UllerichH , SpiekerT , WeckesserM , et al. Detection and differentiation of inflammatory versus fibromatous Crohn's disease strictures: prospective comparison of 18F‐FDG‐PET/CT, MR‐enteroclysis, and transabdominal ultrasound versus endoscopic/histologic evaluation. Inflammatory Bowel Diseases2012;18(12):2252‐60. ">Lenze 2012</a>; <a href="./references#CD012351-bbs2-0062" title="LevineDS . Immunoglobulin therapy in inflammatory bowel disease. Canadian Journal of Gastroenterology1993;7(2):187‐95. ">Levine 1993</a>; <a href="./references#CD012351-bbs2-0063" title="LicataA , RandazzoC , CappelloM , CalvarusoV , ButeraG , FlorenaAM , et al. Fecal calprotectin in clinical practice: A noninvasive screening tool for patients with chronic diarrhea. Journal of Clinical Gastroenterology2012;46(6):504‐8. ">Licata 2012</a>; <a href="./references#CD012351-bbs2-0065" title="MaconiG , CarsanaL , FocianiP , SampietroGM , ArdizzoneS , CristaldiM , et al. Small bowel stenosis in Crohn's disease: clinical, biochemical and ultrasonographic evaluation of histological features. Alimentary Pharmacology and Therapeutics2003;18(7):749‐56. ">Maconi 2003</a>; <a href="./references#CD012351-bbs2-0068" title="MattsSGF . The value of rectal biopsy in the diagnosis of ulcerative colitis. QJM1961;30(4):393‐407. ">Matts 1961</a>; <a href="./references#CD012351-bbs2-0069" title="MazzucchelliL , HauserC , ZgraggenK , WagnerH , HessM , LaissueJ A , et al. Expression of interleukin‐8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. American Journal of Pathology1994;144:997‐1007. ">Mazzucchelli 1994</a>; <a href="./references#CD012351-bbs2-0070" title="MerraG , GasbarriniG , LaterzaL , PizzoferratoM , PosciaA , ScaldaferriF , et al. Propionyl‐L‐carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases. World Journal of Gastroenterology2012;18(36):5065‐71. ">Merra 2012</a>; <a href="./references#CD012351-bbs2-0075" title="NeumannH , ViethM , NeurathMF , AtreyaR . Endocytoscopy allows accurate in vivo differentiation of mucosal inflammatory cells in IBD: a pilot study. Inflammatory Bowel Diseases2013;19(2):356‐62. ">Neumann 2013</a>; <a href="./references#CD012351-bbs2-0077" title="NielsenOH , KirmanI , RudigerN , HendelJ , VainerB . Upregulation of interleukin‐12 and ‐17 in active inflammatory bowel disease. Scandinavian Journal of Gastroenterology2003;38(2):180‐5. ">Nielsen 2003</a>; <a href="./references#CD012351-bbs2-0082" title="ScheurlenC , AllgayerH , HardtM , KruisW . Effect of short‐term topical corticosteroid treatment on mucosal enzyme systems in patients with distal inflammatory bowel disease. Hepatogastroenterology1998;45(23):1539‐45. ">Scheurlen 1998</a>; <a href="./references#CD012351-bbs2-0084" title="SchunkK , ReiterS , KernA , OrthT , WanitschkeR . Hydro‐MRI in inflammatory bowel diseases: a comparison with colonoscopy and histology. RoFo2001;173(8):731‐8. ">Schunk 2001</a>; <a href="./references#CD012351-bbs2-0085" title="SciarrettaG , FurnoA , MazzoniM , BasileC , MalagutiP . Technetium‐99m hexamethyl propylene amine oxime granulocyte scintigraphy in Crohn's disease: diagnostic and clinical relevance. Gut1993;34(10):1364‐9. ">Sciarretta 1993</a>; <a href="./references#CD012351-bbs2-0087" title="ShoenutJP , SemelkaRC , MagroCM , SilvermanR , YaffeCS , MicflikierAB . Comparison of magnetic resonance imaging and endoscopy in distinguishing the type and severity of inflammatory bowel disease. Journal of Clinical Gastroenterology1994;19(1):31‐5. ">Shoenut 1994</a>; <a href="./references#CD012351-bbs2-0088" title="ShynPB , MorteleKJ , Britz‐CunninghamSH , FriedmanS , OdzeRD , BurakoffR , et al. Low‐dose 18F‐FDG PET/CT enterography: improving on CT enterography assessment of patients with Crohn disease. Journal of Nuclear Medicine2010;51(12):1841‐8. ">Shyn 2010</a>; <a href="./references#CD012351-bbs2-0091" title="SmedhK , OlaisonG , FranzenL , SjodahlR . Endoscopic and external bowel changes and histopathology in patients with Crohn's disease. British Journal of Surgery1995;82(2):191‐4. ">Smedh 1995</a>; <a href="./references#CD012351-bbs2-0092" title="SmedhK , OlaisonG , FranzenL , SjodahlR . The endoscopic picture reflects transmural inflammation better than endoscopic biopsy in Crohn's disease. European Journal of Gastroenterology and Hepatology1996;8(12):1189‐93. ">Smedh 1996</a>; <a href="./references#CD012351-bbs2-0094" title="SobhaniI , HochlafS , DenizotY , VissuzaineC , ReneE , BenvenisteJ , et al. Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients. Gut1992;33(9):1220‐5. ">Sobhani 1992</a>; <a href="./references#CD012351-bbs2-0095" title="SolemCA , LoftusEVJr , TremaineWJ , HarmsenWS , ZinsmeisterAR , SandbornWJ . Correlation of C‐reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflammatory Bowel Diseases2005;11(8):707‐12. ">Solem 2005</a>; <a href="./references#CD012351-bbs2-0097" title="VieiraA , FangCB , RolimEG , KlugWA , SteinwurzF , RossiniLG , et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes2009;2:221. ">Vieira 2009</a>; <a href="./references#CD012351-bbs2-0098" title="WardleTD , HallL , TurnbergLA . Use of coculture of colonic mucosal biopsies to investigate the release of eicosanoids by inflamed and uninflamed mucosa from patients with inflammatory bowel disease. Gut1992;33(12):1644‐51. ">Wardle 1992</a>). Twenty studies described 12 numerical instruments that had not undergone any validation testing (<a href="./references#CD012351-bbs2-0019" title="AngYS , MahmudN , WhiteB , ByrneM , KellyA , LawlerM , et al. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Alimentary Pharmacology and Therapeutics2000;14(8):1015‐22. ">Ang 2000</a>; <a href="./references#CD012351-bbs2-0022" title="BariolC , MeagherAP , VickersCR , ByrnesDJ , EdwardsPD , HingM , et al. Thalidomide for inflammatory bowel disease: Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. Journal of Gastroenterology and Hepatology2002;17(2):135‐9. ">Bariol 2002</a>; <a href="./references#CD012351-bbs2-0025" title="Berni CananiR , TerrinG , RapacciuoloL , MieleE , SianiM C , PuzoneC , et al. Faecal calprotectin as reliable non‐invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Digestive and Liver Disease2008;40(7):547‐53. ">Berni 2008</a>; <a href="./references#CD012351-bbs2-0026" title="BernsteinCN , RobertME , EysseleinVE . Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. American Journal of Gastroenterology1993;88:908‐13. ">Bernstein 1993</a>; <a href="./references#CD012351-bbs2-0031" title="BruwerM , SchmidKW , MetzKA , KrieglsteinCF , SenningerN , SchurmannG . Increased expression of metallothionein in inflammatory bowel disease. Inflammation Research2001;50(6):289‐93. ">Bruwer 2001</a>; <a href="./references#CD012351-bbs2-0038" title="D'HaensGR , GeboesK , PeetersM , BaertF , PenninckxF , RutgeertsP . Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology1998;114:262‐7. ">D'Haens 1998</a>; <a href="./references#CD012351-bbs2-0039" title="D'HaensG , SwijsenC , NomanM , LemmensL , CeuppensJ , AgbahiweH , et al. Etanercept in the treatment of active refractory Crohn's disease: a single‐center pilot trial. American Journal of Gastroenterology2001;96(9):2564‐8. ">D'Haens 2001</a>; <a href="./references#CD012351-bbs2-0046" title="FolwacznyC , WiebeckeB , LoeschkeK . Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. American Journal of Gastroenterology1999;94(6):1551‐5. ">Folwaczny 1999</a>; <a href="./references#CD012351-bbs2-0047" title="GirlichC , JungEM , HuberE , OttC , IesalnieksI , SchreyerA , et al. Comparison between preoperative quantitative assessment of bowel wall vascularization by contrast‐enhanced ultrasound and operative macroscopic findings and results of histopathological scoring in Crohn's disease. Ultraschall in der Medizin2011;32(2):154‐9. ">Girlich 2011</a>; <a href="./references#CD012351-bbs2-0051" title="HommesDW , MeenanJ , deHaasM , tenKateFJ , vondem BorneAE , TytgatGN , et al. Soluble Fc gamma receptor III (CD 16) and eicosanoid concentrations in gut lavage fluid from patients with inflammatory bowel disease: reflection of mucosal inflammation. Gut1996;38(4):564‐7. ">Hommes 1996</a>; <a href="./references#CD012351-bbs2-0052" title="IacucciM , Fort GasiaM , HassanC , PanaccioneR , KaplanG , GhoshS , GuiX . Complete mucosal healing defined by endoscopic Mayo sub score still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings. Endoscopy2015;47(8):726‐34. ">Iacucci 2015a</a>; <a href="./references#CD012351-bbs2-0053" title="IacucciM , Fort GasiaM , PanaccioneR , KaplanG , GhoshS , GuiX . Endoscopic assessment of mucosal healing in Crohn's disease by novel iSCAN endoscopic and refined histological gradings. Gastroenterology2015;148(4):S‐638. ">Iacucci 2015b</a>; <a href="./references#CD012351-bbs2-0067" title="MahmudN , McDonaldGS , KelleherD , WeirDG . Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease. Gut1996;38(1):99‐103. ">Mahmud 1996</a>; <a href="./references#CD012351-bbs2-0072" title="MolnarT , FarkasK , NagyF , SzepesZ , TiszlaviczL , NemethI , et al. Does the endoscopic appearance of the ileocecal valve suggest the severity of Crohn's disease in the terminal ileum?. Journal of Crohn's and Colitis2009;3(4):287‐90. ">Molnar 2009</a>; <a href="./references#CD012351-bbs2-0079" title="PullmanWE , SullivanPJ , BarrattPJ , LisingJ , BoothJA , DoeWF . Assessment of inflammatory bowel disease activity by technetium 99m phagocyte scanning. Gastroenterology1988;95(4):989‐96. ">Pullman 1988</a>; <a href="./references#CD012351-bbs2-0080" title="RipollesT , RausellN , ParedesJM , GrauE , MartinezMJ , VizueteJ . Effectiveness of contrast‐enhanced ultrasound for characterisation of intestinal inflammation in Crohn's disease: a comparison with surgical histopathology analysis. Journal of Crohn's and Colitis2013;7(2):120‐8. ">Ripolles 2013</a>; <a href="./references#CD012351-bbs2-0081" title="SaverymuttuSH , CamilleriM , ReesH . Indium 111‐granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal Indium 111‐granulocyte excretion. Gastroenterology1986;90:1121‐8. ">Saverymuttu 1986</a>; <a href="./references#CD012351-bbs2-0089" title="SilvaMA , MenezesJ , WizmanS , GendronR , OlignyL , SeidmanEG . Cytokine tissue levels as markers of disease activity in pediatric Crohn disease. Pediatric Research2003;54:456‐61. ">Silva 2003</a>; <a href="./references#CD012351-bbs2-0090" title="SilvaMA , LopezCB , RiverinF , OlignyL , MenezesJ , SeidmanEG . Characterization and distribution of colonic dendritic cells in Crohn's disease. Inflammatory Bowel Diseases2004;10(5):504‐12. ">Silva 2004</a>; <a href="./references#CD012351-bbs2-0096" title="StewardMJ , PunwaniS , ProctorI , Adjei‐GyamfiY , ChatterjeeF , BloomS , et al. Non‐perforating small bowel Crohn's disease assessed by MRI enterography: derivation and histopathological validation of an MR‐based activity index. European Journal of Radiology2012;81(9):2080‐8. ">Steward 2012</a>). Many histological disease activity indices were incorporated into composite scores together with endoscopic, surgical and radiologic findings (e.g. <a href="./references#CD012351-bbs2-0055" title="KolkmanJJ , FalkeTH , RoosJC , VanDijkDH , BanninkIM , DenHollanderW , et al. Computed tomography and granulocyte scintigraphy in active inflammatory bowel disease. Comparison with endoscopy and operative findings. Digestive Diseases and Sciences1996;41(4):641‐50. ">Kolkman 1996</a>; <a href="./references#CD012351-bbs2-0056" title="KoutroubakisIE , KoukourakiSI , DimouliosPD , VelidakiAA , KarkavitsasNS , KouroumalisEA . Active inflammatory bowel disease: evaluation with 99mTc (V) DMSA scintigraphy. Radiology2003;229(1):70‐4. ">Koutroubakis 2003</a>; <a href="./references#CD012351-bbs2-0059" title="LasockiA , PitmanA , WilliamsR , LuiB , KaladeA V , FarishS . Relative efficacy of different MRI signs in diagnosing active Crohn's disease, compared against a histological gold standard. Journal of Medical Imaging and Radiation Oncology2011;55(1):11‐9. ">Lasocki 2011</a>; <a href="./references#CD012351-bbs2-0060" title="LeddinDJ , PatersonWG , DaCostaLR , DindaPK , DepewWT , MarkotichJ , et al. Indium‐111‐labeled autologous leukocyte imaging and fecal excretion. Comparison with conventional methods of assessment of inflammatory bowel disease. Digestive Diseases and Sciences1987;32(4):377‐87. ">Leddin 1987</a>; <a href="./references#CD012351-bbs2-0061" title="LenzeF , WesslingJ , BremerJ , UllerichH , SpiekerT , WeckesserM , et al. Detection and differentiation of inflammatory versus fibromatous Crohn's disease strictures: prospective comparison of 18F‐FDG‐PET/CT, MR‐enteroclysis, and transabdominal ultrasound versus endoscopic/histologic evaluation. Inflammatory Bowel Diseases2012;18(12):2252‐60. ">Lenze 2012</a>). </p> <p>Among studies using a numerical histological index, the main reasons for exclusion were absence of data on the development or assessment of operating properties of the histological scoring systems (<a href="./references#CD012351-bbs2-0026" title="BernsteinCN , RobertME , EysseleinVE . Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. American Journal of Gastroenterology1993;88:908‐13. ">Bernstein 1993</a>; <a href="./references#CD012351-bbs2-0031" title="BruwerM , SchmidKW , MetzKA , KrieglsteinCF , SenningerN , SchurmannG . Increased expression of metallothionein in inflammatory bowel disease. Inflammation Research2001;50(6):289‐93. ">Bruwer 2001</a>; <a href="./references#CD012351-bbs2-0038" title="D'HaensGR , GeboesK , PeetersM , BaertF , PenninckxF , RutgeertsP . Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology1998;114:262‐7. ">D'Haens 1998</a>; <a href="./references#CD012351-bbs2-0039" title="D'HaensG , SwijsenC , NomanM , LemmensL , CeuppensJ , AgbahiweH , et al. Etanercept in the treatment of active refractory Crohn's disease: a single‐center pilot trial. American Journal of Gastroenterology2001;96(9):2564‐8. ">D'Haens 2001</a>; <a href="./references#CD012351-bbs2-0046" title="FolwacznyC , WiebeckeB , LoeschkeK . Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. American Journal of Gastroenterology1999;94(6):1551‐5. ">Folwaczny 1999</a>; <a href="./references#CD012351-bbs2-0047" title="GirlichC , JungEM , HuberE , OttC , IesalnieksI , SchreyerA , et al. Comparison between preoperative quantitative assessment of bowel wall vascularization by contrast‐enhanced ultrasound and operative macroscopic findings and results of histopathological scoring in Crohn's disease. Ultraschall in der Medizin2011;32(2):154‐9. ">Girlich 2011</a>; <a href="./references#CD012351-bbs2-0051" title="HommesDW , MeenanJ , deHaasM , tenKateFJ , vondem BorneAE , TytgatGN , et al. Soluble Fc gamma receptor III (CD 16) and eicosanoid concentrations in gut lavage fluid from patients with inflammatory bowel disease: reflection of mucosal inflammation. Gut1996;38(4):564‐7. ">Hommes 1996</a>; <a href="./references#CD012351-bbs2-0053" title="IacucciM , Fort GasiaM , PanaccioneR , KaplanG , GhoshS , GuiX . Endoscopic assessment of mucosal healing in Crohn's disease by novel iSCAN endoscopic and refined histological gradings. Gastroenterology2015;148(4):S‐638. ">Iacucci 2015b</a>; <a href="./references#CD012351-bbs2-0072" title="MolnarT , FarkasK , NagyF , SzepesZ , TiszlaviczL , NemethI , et al. Does the endoscopic appearance of the ileocecal valve suggest the severity of Crohn's disease in the terminal ileum?. Journal of Crohn's and Colitis2009;3(4):287‐90. ">Molnar 2009</a>; <a href="./references#CD012351-bbs2-0079" title="PullmanWE , SullivanPJ , BarrattPJ , LisingJ , BoothJA , DoeWF . Assessment of inflammatory bowel disease activity by technetium 99m phagocyte scanning. Gastroenterology1988;95(4):989‐96. ">Pullman 1988</a>; <a href="./references#CD012351-bbs2-0080" title="RipollesT , RausellN , ParedesJM , GrauE , MartinezMJ , VizueteJ . Effectiveness of contrast‐enhanced ultrasound for characterisation of intestinal inflammation in Crohn's disease: a comparison with surgical histopathology analysis. Journal of Crohn's and Colitis2013;7(2):120‐8. ">Ripolles 2013</a>; <a href="./references#CD012351-bbs2-0089" title="SilvaMA , MenezesJ , WizmanS , GendronR , OlignyL , SeidmanEG . Cytokine tissue levels as markers of disease activity in pediatric Crohn disease. Pediatric Research2003;54:456‐61. ">Silva 2003</a>; <a href="./references#CD012351-bbs2-0090" title="SilvaMA , LopezCB , RiverinF , OlignyL , MenezesJ , SeidmanEG . Characterization and distribution of colonic dendritic cells in Crohn's disease. Inflammatory Bowel Diseases2004;10(5):504‐12. ">Silva 2004</a>; <a href="./references#CD012351-bbs2-0096" title="StewardMJ , PunwaniS , ProctorI , Adjei‐GyamfiY , ChatterjeeF , BloomS , et al. Non‐perforating small bowel Crohn's disease assessed by MRI enterography: derivation and histopathological validation of an MR‐based activity index. European Journal of Radiology2012;81(9):2080‐8. ">Steward 2012</a>); inclusion of paediatric patients (<a href="./references#CD012351-bbs2-0025" title="Berni CananiR , TerrinG , RapacciuoloL , MieleE , SianiM C , PuzoneC , et al. Faecal calprotectin as reliable non‐invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Digestive and Liver Disease2008;40(7):547‐53. ">Berni 2008</a>; <a href="./references#CD012351-bbs2-0089" title="SilvaMA , MenezesJ , WizmanS , GendronR , OlignyL , SeidmanEG . Cytokine tissue levels as markers of disease activity in pediatric Crohn disease. Pediatric Research2003;54:456‐61. ">Silva 2003</a>; <a href="./references#CD012351-bbs2-0090" title="SilvaMA , LopezCB , RiverinF , OlignyL , MenezesJ , SeidmanEG . Characterization and distribution of colonic dendritic cells in Crohn's disease. Inflammatory Bowel Diseases2004;10(5):504‐12. ">Silva 2004</a>); and inclusion of ulcerative colitis patients without separately reported data for patients with ulcerative colitis and Crohn's disease (<a href="./references#CD012351-bbs2-0019" title="AngYS , MahmudN , WhiteB , ByrneM , KellyA , LawlerM , et al. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Alimentary Pharmacology and Therapeutics2000;14(8):1015‐22. ">Ang 2000</a>; <a href="./references#CD012351-bbs2-0022" title="BariolC , MeagherAP , VickersCR , ByrnesDJ , EdwardsPD , HingM , et al. Thalidomide for inflammatory bowel disease: Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. Journal of Gastroenterology and Hepatology2002;17(2):135‐9. ">Bariol 2002</a>; <a href="./references#CD012351-bbs2-0052" title="IacucciM , Fort GasiaM , HassanC , PanaccioneR , KaplanG , GhoshS , GuiX . Complete mucosal healing defined by endoscopic Mayo sub score still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings. Endoscopy2015;47(8):726‐34. ">Iacucci 2015a</a>; <a href="./references#CD012351-bbs2-0067" title="MahmudN , McDonaldGS , KelleherD , WeirDG . Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease. Gut1996;38(1):99‐103. ">Mahmud 1996</a>; <a href="./references#CD012351-bbs2-0081" title="SaverymuttuSH , CamilleriM , ReesH . Indium 111‐granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal Indium 111‐granulocyte excretion. Gastroenterology1986;90:1121‐8. ">Saverymuttu 1986</a>). </p> <p>Among the studies that evaluated a non‐numerical index, the main reasons for exclusion were usage of a stepwise histological scoring index; the absence of a specific description of the histological scoring index (<a href="./references#CD012351-bbs2-0029" title="BorodyTJ , LeisS , WarrenEF , SuraceR . Treatment of severe Crohn's disease using antimycobacterial triple therapy‐‐approaching a cure?. Digestive and Liver Disease2002;34(1):29‐38. ">Borody 2002</a>; <a href="./references#CD012351-bbs2-0037" title="D'HaensG , GeboesK , PonetteE , PenninckxF , RutgeertsP . Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology1997;112(5):1475‐81. ">D'Haens 1997</a>; <a href="./references#CD012351-bbs2-0058" title="LabaereD , SmismansA , VanOlmenG , ChristiaensP , D'HaensG , MoonsV , et al. Clinical comparison of eight different calprotectin immunoassays for the diagnosis and follow‐up of inflammatory bowel disease. Journal of Crohn's and Colitis2013;7:S120. ">Labaere 2013</a>; <a href="./references#CD012351-bbs2-0064" title="LofbergR , NeurathM , OstA , PetterssonS . Topical NFkB p65 antisense oligonucleotides in patients with active distal colonic IBD. A randomised, controlled pilot trial. Gastroenterology2002;122(4):A60. ">Lofberg 2002</a>; <a href="./references#CD012351-bbs2-0066" title="MacorittoM , HoangV , ThomsonT , LaifenfeldD , DrubinD . A novel mechanistic biomarker panel predicts response to infliximab in patients with Crohn's disease. Inflammatory Bowel Diseases2012;18:S61. ">Macoritto 2012</a>; <a href="./references#CD012351-bbs2-0071" title="MigaledduV , ScanuAM , QuaiaE , RoccaPC , DoreMP , ScanuD , et al. Contrast‐enhanced ultrasonographic evaluation of inflammatory activity in Crohn's disease. Gastroenterology2009;137(1):43‐52. ">Migaleddu 2009</a>; <a href="./references#CD012351-bbs2-0073" title="NeagaM , NutiF , DelGiudiceE , CivitelliF , ViolaF , AloiM , et al. Non invasive stool markers in assessing bowel inflammation in children with inflammatory bowel disease. Digestive and Liver Disease2009;41S (S3):S210. ">Neaga 2009</a>; <a href="./references#CD012351-bbs2-0074" title="NeumannH , ViethM , AtreyaR , GrauerM , GuntherC , NeurathM . Virtual chromoendoscopy with i‐scan for diagnosis of mucosal healing in patients with inflammatory bowel disease a prospective randomized double‐blind controlled study. Journal of Crohn's and Colitis2012;6:S54. ">Neumann 2012</a>; <a href="./references#CD012351-bbs2-0076" title="NichollsS , DomizioP , WilliamsCB , DawnayA , BraeggerCP , MacDonaldTT , et al. Cyclosporin as initial treatment for Crohn's disease. Archives of Disease in Childhood1994;71:243‐7. ">Nicholls 1994</a>; <a href="./references#CD012351-bbs2-0078" title="PlesecTP , ShenB , RemziF , FazioV , BennettAE , GoldblumJR . Ischemic pouchitis (IP): A histologic evaluation and comparison to Crohn's disease of the pouch (CDP) and antibiotic‐responsive pouchitis (ARP). Laboratory Investigation2009;89:146A. ">Plesec 2009</a>; <a href="./references#CD012351-bbs2-0083" title="Schmitz‐MoormannP , BrandesJW , JesdinskyH , KnappM . Relationships between blood chemistry and histology of the rectal mucosa in Crohn's disease. Pathology, Research and Practice1988;183(1):35‐8. ">Schmitz‐Moormann 1988</a>; <a href="./references#CD012351-bbs2-0086" title="SeldenrijkCA , MorsonBC , MeuwissenSG , SchipperNW , LindemanJ , MeijerCJ . Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: diagnostic implications. Gut1991;32(12):1514‐20. ">Seldenrijk 1991</a>); and study design (i.e. animal study) (<a href="./references#CD012351-bbs2-0015" title="AbadC , Cheung‐LauG , Coute‐MonvoisinAC , WaschekJA . Vasoactive intestinal peptide‐deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid‐induced colitis. Neuroimmunomodulation2015;22(3):203‐12. ">Abad 2014</a>). </p> </section> </section> <section id="CD012351-sec-0046"> <h3 class="title">Risk of bias in included studies</h3> <p><b>Blinding</b> </p> <p>The presence or absence of blinding to clinical and endoscopic information was not routinely reported. In two studies, pathologists were fully blinded to clinical and endoscopic information (<a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a>; <a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a>). In three studies, pathologists were blinded to clinical information (<a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a>; <a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a>; <a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a>), but it was not reported if they were blinded to endoscopic information as well. Four studies reported that pathologists were blinded but did not report more precisely if blinding was performed with respect to clinical and endoscopic information (<a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a>; <a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a>; <a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a>). In three studies, pathologists were blinded only to the treatment patients received in the clinical trial (<a href="./references#CD012351-bbs2-0002" title="BaertF J , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22‐8. ">Baert 1999</a>; <a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a>; <a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a>). Finally, two studies did not report if the pathologists were blinded to clinical and endoscopic information (<a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a>, <a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a>) (<a href="#CD012351-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD012351-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012351-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012351.pub2/media/CDSR/CD012351/image_n/nCD012351-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <p><b>Independent observation</b> </p> <p>In the majority of studies the histological assessment of biopsy specimens was performed by a single pathologist (<a href="./references#CD012351-bbs2-0002" title="BaertF J , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22‐8. ">Baert 1999</a>; <a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a>; <a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a>; <a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a>; <a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a>; <a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a>; <a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a>; <a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a>; <a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a>). As a result, independent observation by pathologists was not relevant, but differences in training and expertise could naturally account for variation in results. In phase one of <a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a>, pathologists performed scoring independently, however it was unclear whether independent observation was performed in phase two. In phase three, scoring was performed by a single pathologist and independent observation was not relevant. <a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a> did not report on independent observation. There is a potential concern that scorings between the pathologists were not consistent because inter‐rater reliability was not reported. <a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a> and <a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a> did not report on the number of pathologists who scored the biopsies or whether the histological assessments were made independently. It is possible that a single pathologist examined the biopsy specimens, or that independent observation of histopathology was not considered in the clinical trial (<a href="#CD012351-fig-0002">Figure 2</a>). </p> <p><b>Methodological quality</b> </p> <p>The COSMIN tool was used to assess methodological quality of the included studies (see <a href="#CD012351-tbl-0003">Table 3</a>; <a href="#CD012351-tbl-0004">Table 4</a>). </p> <div class="table" id="CD012351-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of operating properties of histologic scoring indices for Crohn's disease</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scoring index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Reliability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Responsiveness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Feasibility</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Content validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criterion validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Construct validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intra‐rater</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inter‐rater</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Test‐retest</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Internal consistency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AHS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGHAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dieleman Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GHAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+/‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drews Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gomes Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+/‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saverymuttu Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ward Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+/‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IGHAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+/‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sipponen Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laharie Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regueiro Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agnholt Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naini and Cortina Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>+ positive rating</p> <p>? no information or indeterminate rating</p> <p>‐ Negative rating</p> </div> </div> <div class="table" id="CD012351-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">The methodological quality of histologic index measurement properties as described in the original development articles (COSMIN checklist)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>B</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>C</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>E</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>F</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>G</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>H</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>I</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>J</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Internal consistency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reliability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measurement</b> </p> <p><b>error</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Construct validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Factor analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypothesis</b> </p> <p><b>testing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross‐cultural validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criterion</b> </p> <p><b>validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Responsiveness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interpretability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Generlisability</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>pre‐treatment 2.0 (IQR 1‐3)</p> <p>post‐treatment 1.0 (IQR 0‐3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) age (range): female/male: 33 (27‐50), 40 (18‐67)</p> <p>2) female/male: 14/12</p> <p>3) disease characteristics and duration of treatment:</p> <p>see table Characteristics of included studies</p> <p>4) setting: prospective single‐centre trial at Aarhus university hospital</p> <p>5) country: Denmark</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0002" title="BaertF J , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22‐8. ">Baert 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>A) Colonic</p> <p>Mean decrease in colonic specimens:</p> <p>infliximab arm (n = 11): from 8.3 (1‐12) to 3.4 (0‐7)</p> <p>placebo arm (n = 2): from 6.5 (6‐7) to 6 (5‐7)</p> <p>B) Ileal:</p> <p>Mean decrease in ileal specimens:</p> <p>infliximab arm (n = 6): from 8.2 (2‐12) to 2.3 (0‐6)</p> <p>placebo arm (n = 4): from 6.8 (1‐10) to 6.3 (4‐10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Age (range): placebo arm 32.6 (25‐41), infliximab arm 32.07 (20‐47)</p> <p>2) Female/male: 12/6</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: Single‐centre, placebo‐controlled, randomised trial at University hospital Gasthuisberg, Leuven </p> <p>5) country: Belgium</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>A) Colonic</p> <p>infliximab arm (n = 7): before 8.8+/‐1.7 (range, 2‐10) and after infusion of infliximab 2.7+/‐1.7 (range, 0‐8) </p> <p>placebo arm (n = 4): before 11.0+/‐2.3 and after infusion of placebo 9.0+/‐1.9</p> <p>B) Ileal:</p> <p>infliximab arm (n = 4): before 7.7+/‐2.3 (range, 4‐12) and after infusion of infliximab 3.3+/‐2.0 (range, 0‐7) </p> <p>placebo arm (n = 3): before 9.2+/‐2.4 and after infusion of placebo 8.7+/‐3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>data for the whole cohort ‐ not described for patients with histologic assessment only: </p> <p>1) mean age: placebo arm 34.4 (+/‐ 9.8), infliximab arm 31.4 (+/‐ 7.1)</p> <p>2) Female/male: 18/12</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: international multi‐centre, randomised, placebo‐controlled trial, biopsies specimens taken only in one centre (University hospital Gasthuisberg, Leuven) </p> <p>5) countries: biopsies only in Belgium</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores (n = 32):</p> <p>stage 0: 8 (25%)</p> <p>stage 1: 5 (16%)</p> <p>stage 2: 10 (31%)</p> <p>stage 3: 3 (9%)</p> <p>stage 4: 6 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Mean age (range): 38.75 (17‐71)</p> <p>2) Female/male: 18/14</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: retrospective analysis from a single centre</p> <p>5) countries: Germany</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fair (CGHAS)</p> <p>and poor (IGHAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fair (CGHAS)</p> <p>and poor (IGHAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>A) Median CGHAS</p> <p>SIngle dose/episodic group:</p> <p>10 (week 0), 4 (week 10) and 5 (week 54)</p> <p>Combined maintenance/episodic group:</p> <p>9 (week 0), 2 (week 10) and 2 (week 54)</p> <p>B) Median IGHAS</p> <p>SIngle dose/episodic group:</p> <p>1 (week 0), 1 (week 10) and 2 (week 54)</p> <p>Combined maintenance/episodic group:</p> <p>2 (week 0), 0 (week 10) and 0 (week 54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Median age: 30</p> <p>2) Female/male: 28/20</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: international multi‐centre, randomised, controlled trial in European centres</p> <p>5) countries: European (not reported which countries)</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of histologic scores:</p> <p>range 0‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Age: not reported</p> <p>2) Female/male: not reported</p> <p>3) disease characteristics and duration of treatment: not reported</p> <p>4) setting: prospective, single centre trial</p> <p>5) countries: USA</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>methotrexate arm (n = 12): median 2.5, range 1‐12</p> <p>azathioprine arm (n = 14): median 3, range 0‐11</p> <p>infliximab arm (n = 14): median 3.5, range 0‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>data for the whole cohort ‐ not described for patients with histologic assessment only: </p> <p>1) Median age (range): methotrexate arm (n = 18) 40 (21‐56), azathioprine arm (n = 18) 48 (21‐89), infliximab arm (n = 15) 46 (30‐79) </p> <p>2) Female/male: 38/13</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: prospective single‐centre study at the Haut‐Leveque hospital</p> <p>5) country: France</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>Azathioprine arm: from 5.92+/‐1.7 at baseline to 2.92+/‐1.93 at study termination</p> <p>Budesonide arm:</p> <p>from 5.72+/‐1.63 at baseline to 6.01+/‐1.72 at study termination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Median age (range): azathioprine arm (n = 38) 34.3 (19‐59), budesonide arm (n = 39) 34.5 (19‐62) </p> <p>2) Female/male: 43/34</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: prospective single‐centre, randomised, controlled study in Athens</p> <p>5) country: Greece</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) the distribution of scores (total and IBD):</p> <p>Ileal scores (max. of 10) ranged from 0 to 8</p> <p>Colonic scores (max. of 17) ranged from 0 to 13</p> <p>2) scores for relevant subgroups</p> <p>(ileal score: mean (SD), colonic score: mean (SD))</p> <p>ulcerative colitis 0,65 (1.5), 9.4 (2.8)</p> <p>Crohn's disease 3.5 (2.4), 5.2 (3.6)</p> <p>IBD unclassified 0, 5.9 (3.7)</p> <p>non‐IBD chronic ileocolitis 0.5 (0.7), 3.4 (2.9)</p> <p>nonspecific chronic ileocolitis 3.0 (3.5), 4.5 (1.7)</p> <p>no chronic ileocolitis 0.3 (0.8),1.0 (1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) mean age (range) for subgroups:</p> <p>ulcerative colitis 26 (11‐43), Crohn's disease 32 (13‐57),</p> <p>IBD unclassified 34 (17‐51), non‐IBD chronic</p> <p>ileocolitis 53 (25‐81), nonspecific chronic</p> <p>ileocolitis 53 (43‐63), no chronic ileocolitis 47 (15‐89)</p> <p>2) male/female: 59/105</p> <p>3) disease characteristics and duration of treatment:</p> <p>see table Characteristics of included studies</p> <p>4) setting: study with 2 retrospective phases (calibration and validation) and a prospective phase (application) in a single centre </p> <p>5) country: USA</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>score 0‐3: 12 patients</p> <p>score 4‐6: 3 patients</p> <p>score 7‐14: 9 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Median age: infliximab arm 43, placebo arm 32</p> <p>2) Female/male: 8/16</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: randomised, two‐armed, double blinded, placebo‐controlled trial at the University of Pittsburgh Medical Centre </p> <p>5) country: USA</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>in ileocolonic or colonic disease, median total histology score was 15 (range 0‐45), ileal histology score 4 (0‐11) and histology score of the colon 13 (0‐38). </p> <p>In the ileal disease, ileal histology score was 6 (0‐10).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Median age (range): 33 (19‐70)</p> <p>2) Female/male: 31/30</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: prospective single‐center study</p> <p>5) country: Finland</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>Naltrexone arm (n = 18):</p> <p>from 16 before treatment to 6 after treatment</p> <p>Placebo arm (n = 16):</p> <p>18 before and after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Mean age (range): naltrexone arm 40.5 (21‐60), placebo arm 44.8 (26‐67)</p> <p>2) Female %: naltrexone arm 64.7%, placebo arm 62.5 %</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: prospective, double blind, randomised placebo‐controlled trial at a single centre </p> <p>5) countries: USA</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores (n = 27):</p> <p>group 1: 3.0 (0.7‐6)</p> <p>group 2: 3.2 (0.7‐5.3)</p> <p>group 3: 3.5 (1.7‐6.7)</p> <p>group 4: 4.9 (3.3‐7.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Mean age at onset (range): group Good 34.7 (19‐68), group Moderate 22.4 (17‐36), group Colectomy 39.1 (18‐49), group Death 38.5 (13‐62) </p> <p>2) Female/male: 12/15</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: retrospective study at a single centre</p> <p>5) countries: Scotland, United Kingdom</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>A) terminal ileum</p> <p>Before treatment (n = 28):</p> <p>grade 0: 2 (7%), grade 1: 8 (29%), grade 2: 11 (39%), grade 3: 77 (25%)</p> <p>After treatment (n = 28):</p> <p>grade 0: 7 (25%), grade 1: 8 (29%), grade 2: 10 (36%), grade 3: 3 (11%)</p> <p>B) colon</p> <p>Before treatment (n = 28):</p> <p>grade 0: 8 (29%), grade 1: 8 (29%), grade 2: 7 (25%), grade 3: 5 (18%)</p> <p>After treatment (n = 28):</p> <p>grade 0: 12 (43%), grade 1: 8 (29%), grade 2: 6 (21%), grade 3: 2 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Median age (interquartile range): 28 (22‐36)</p> <p>2) Female/male:12/16</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: prospective, single centre, pilot trial</p> <p>5) countries: Japan</p> <p>6) language: not relevant</p> </td> </tr> </tbody> </table> </div> <p>In total, seven studies assessed criterion validity for any histological scoring index. With regard to methodological quality, one of these studies was rated as 'good' (<a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a>), two were rated as 'fair' (<a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> (for the CGHAS); <a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a>) and five were rated as 'poor' (<a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> (for the IGHAS); <a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a>; <a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a>; <a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a>; <a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a>). </p> <p>Four studies assessed construct validity. With regard to methodological quality, two of these studies were rated as 'fair' (<a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> (for the CGHAS); <a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a>) and three were rated as 'poor' (<a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a>; <a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> (for the IGHAS); <a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a>). </p> <p>One study assessed reliability and with regard to methodological quality, it was rated as 'good' (Naini 2012). </p> <p>Seven studies assessed responsiveness for any histological scoring index. With regard to methodological quality, one of these studies was rated as 'fair' (<a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a>) and six were rated as 'poor' (<a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a>; <a href="./references#CD012351-bbs2-0002" title="BaertF J , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22‐8. ">Baert 1999</a>; <a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a>; <a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a>; <a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a>). </p> <p>One of the included studies assessed feasibility (Naini 2012).</p> </section> <section id="CD012351-sec-0047"> <h3 class="title" id="CD012351-sec-0047">Effect of methods</h3> <p><b>Reliability</b> </p> <p>One study assessed inter‐rater reliability (<a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a>). In phase one and phase two of the Naini and Cortina Score development paper, agreement between two pathologists was measured. In phase one, which included ten patients, there was 'almost perfect' agreement for both ileitis and colitis scores generated by the pathologists, as demonstrated by correlation coefficients of r = 0.96 and 0.95, respectively. Phase two, which included 164 patients and a minor modification of the score, reaffirmed 'almost perfect' agreement between pathologists. The correlation coefficients were r = 0.94 for scoring of both ileitis and colitis (<a href="#CD012351-tbl-0005">Table 5</a>). </p> <div class="table" id="CD012351-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Reliability</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inter‐rater Kappa</b> </p> <p><b>(between raters)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inter‐rater ICC</b> </p> <p><b>(between raters)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intra‐rater</b> </p> <p><b>Kappa</b> </p> <p><b>(within rater)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intra‐rater ICC</b> </p> <p><b>(within rater)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Internal Consistency</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naini and Cortina score</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phase I</p> <p>(before score modification):</p> <p>Ileitis ICC: 0.96</p> <p>Colitis ICC: 0.95</p> <p>Phase II</p> <p>Ileitis ICC: 0.94</p> <p>Colitis ICC: 0.94</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ICC, interclass correlation coefficient</p> </div> </div> <p>None of the included studies assessed intra‐rater reliability, test‐retest reliability, or internal consistency. </p> <p><b>Validity</b> </p> <p><i><b>Content validity</b> </i> </p> <p>None of the included studies assessed the content validity of histological scoring indices for Crohn's disease. </p> <p><i><b>Criterion validity</b> </i> </p> <p>Correlation estimates between the histological scoring indices and objective biomarkers (i.e. CRP, ESR, fecal calprotectin and fecal lactoferrin) were 'fair' to 'moderate' (ranging from r = 0.25 to 0.56) and reported in two studies (<a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a>; <a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a>; See <a href="#CD012351-tbl-0006">Table 6</a>). </p> <div class="table" id="CD012351-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Criterion Validity</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Correlation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histology score by Gomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.34 (P valued not stated)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histology score by Gomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.25 (P valued not stated)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileal GHAS (modified GHAS by Sipponen)</p> <p>Colonic GHAS (modified GHAS by Sipponen)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Faecal calprotectin</p> <p>(quantitative enzyme immunoassay, PhiCal Test, Calpro AS, Oslo, Norway, values &lt; 100 mcg/g stoll considered normal) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileal GHAS: r = 0.311 (P valued not stated)</p> <p>Colonic GHAS: r = 0.563 (P &lt; 0.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileal GHAS (modified GHAS by Sipponen)</p> <p>Colonic GHAS (modified GHAS by Sipponen)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Faecal lactoferrin</p> <p>(quantitative enzyme immunoassay, IBD‐SCAN, Inverness Medical, Princeton, NJ, USA, Techlab, Blacksburg, VA, USA, values &lt; 7.25 mcg/g stoll considered normal) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileal GHAS: r = 0.291 (P valued not stated)</p> <p>Colonic GHAS: r = 0.543 (P &lt; 0.01)</p> </td> </tr> </tbody> </table> </div> <p><b>CRP </b> </p> <p>One study investigated the correlation between a histological scoring system (the Gomes Score) and CRP (<a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a>). The estimate of correlation was 'fair', with r = 0.34 (P value not stated). </p> <p><b>ESR </b> </p> <p>One study explored the relationship between the Gomes Score and ESR (<a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a>). The estimate of correlation was r = 0.25 (P value not reported), indicating 'fair' agreement. </p> <p><b>Fecal calprotectin </b> </p> <p>For the Sipponen Score, the estimate of correlation was 'fair' (r = 0.31) for the modification of the ileal GHAS and 'moderate' (r = 0.56) for the modification of the colonic GHAS (<a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a>). However, it should be noted that the P value of the former was not statistically significant, while P &lt; 0.01 for the latter. </p> <p><b>Fecal lactoferrin </b> </p> <p>The estimate of correlation between stool lactoferrin and the ileal Sipponen Score was 'fair', with r = 0.29, however this agreement was not statistically significant. Agreement between stool lactoferrin and the colonic component of the Sipponen Score was 'moderate', with r = 0.54 (P &lt; 0.001) (<a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a>). </p> <p><i><b>Construct validity</b> </i> </p> <p>A total of nine Crohn's disease scoring indices have been tested for construct validity (<a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a>; <a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a>; <a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a>; <a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a>; <a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a>; <a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a>; <a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a>; <a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a>; <a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a>). The correlation estimates between the histologic scoring indices and other measures of disease activity (i.e. clinical and endoscopic measurement tools) ranged from 'slight' to 'substantial'. The Agnholt Score, Drews Score and Geboes score were compared to the CDAI, the most commonly used clinical measure of disease activity. The estimate of correlation between the Aghholt Score and the CDAI was found to be r = 0.5 (P = 0.019) at week zero and r = 0.6 (P = 0.002) at week eight (<a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a>). For the Drews Score, a non‐statistically significant correlation of r = 0.25 was observed (<a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a>). In <a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a>, the correlation estimates for the colonic GHAS and ileal GHAS were r = 0.43 and r = 0.10, respectively. While the correlation estimate for the colonic GHAS (P = 0.001) was statistically significant, this was not the case for the ileal GHAS (P = 0.700). The Gomes Score was compared to the Harvey Bradshaw index, however, no statistically significant agreement was observed (<a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a>). The colonic and ileal GHAS scores proposed by <a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> were also compared to the Inflammatory Bowel Disease Questionnaire (IBDQ). At weeks 10 and 54, the correlation estimates between the colonic GHAS and IBDQ were ‐0.33 (P = 0.037) and ‐0.04 (P = 0.873), respectively. For the ileal GHAS, the estimates of correlation with the IBDQ at weeks 10 and 54 were ‐0.29 (P = 0.132) and ‐0.35 (P = 0.246), respectively (<a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a>). </p> <p>Four measures of endoscopic activity were used as comparisons: the Crohn's Disease Endoscopic Index of Severity (CDEIS), Gomes Score (endoscopic), Simple Endoscopic Score for Crohn's Disease (SES‐CD), and Rugteerts Score. For the colonic GHAS described by <a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a>, the estimate of correlation with the CDEIS was r = 0.56. Although there was a statistically significant correlation between change in CDEIS and change in CGHAS from week 0 to week 10 was (r = 0.52, P = 0.001), the correlation coefficient was not statistically significant from week 0 to week 54. For the ileal GHAS, the estimate of correlation with the CDEIS was not statistically significant (<a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a>). With respect to the modified GHAS proposed by <a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a>, no significant correlation between the new index and the CDEIS or SES‐CD was observed. For the ileal GHAS as modified by <a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a>, the estimates of correlation with ileal SES‐CD were r = 0.779, and r = 0.759 for the modified colonic GHAS. The correlation estimate between the modified GHAS developed by Regueiro and the Rutgeert's endoscopic score was r = 0.73. In <a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a>, novel histologic and endoscopic scores were compared; the estimate of correlation between the new scores was r = 0.76. </p> <p>In the study by <a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a>, the authors assessed whether the histological score could predict prognosis and disease sequelae in the future. At baseline, the Ward Score was capable of differentiating between symptomatic and asymptomatic patients, and those who died as a direct result of Crohn's disease, however no other statistically significant differences among groups were observed (<a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a>). </p> <p>The Naini and Cortina Score was not developed to assess histological disease activity but to standardise histological assessment of chronic ileocolitis and diagnose IBD. In the validation phase, the authors aimed to confirm that IBD cases would consistently receive high scores. Retrospective scoring of mucosal biopsies of 164 patients who had undergone colonoscopy for clinical suspicion of ileocolitis was performed. Subsequently, the clinical diagnosis was revealed and compared to the histologic score. Cases of IBD consistently scored higher than cases of suspected ileocolitis. For the diagnosis of IBD, an ileal score of five or greater had an 88% positive predictive value (PPV), whereas a colitis score of nine or greater had a 92% PPV. Ileal scores of three and four had a 53% PPV, and for scores of two or less, the PPV was 19%. Likewise, colonic scores of four and eight had a PPV of 52%, and for scores three or less, the PPV was 8% (Naini 2012) (<a href="#CD012351-tbl-0007">Table 7</a>). </p> <div class="table" id="CD012351-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Construct Validity</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Correlation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agnholt Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>week 0: r = 0.5 (P = 0.019)</p> <p>week 8: r = 0.6 (P = 0.002)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drews Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no significant association (P = 0.2482)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geboes Score (colonic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>change from week 0 to week 10: r = 0.43 (P = 0.006, n = 40)</p> <p>change from week 0 to week 54: r = 0.10 (P = 0.700, n = 17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geboes Score (ileal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>change from week 0 to week 10: r = 0.27 (P = 0.155, n = 29)</p> <p>change from week 0 to week 54: r = 0.68 (P = 0.001, n = 13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geboes Score (colonic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBDQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>change from week 0 to week 10: r = ‐0.33 (P = 0.037, n = 40)</p> <p>change from week 0 to week 54: r = ‐0.04 (P = 0.873, n = 17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geboes Score (ileal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBDQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>change from week 0 to week 10: r = ‐0.29 (P = 0.132, n=29)</p> <p>change from week 0 to week 54: r = ‐0.35 (P = 0.246, n=13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geboes Score (colonic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>at week 0: r = 0.56 (P &lt; 0.001, n = 45)</p> <p>change from week 0 to week 10: r = 0.52 (P = 0.001, n = 40)</p> <p>change from week 0 to week 54: r = 0.40 (P = 0.110, n = 17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geboes Score (ileal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>change from week 0 to week 10: r = 0.05 (P = 0.78, n = 29)</p> <p>change from week 0 to week 54: r = 0.42 (P = 0.153, n = 13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gomes Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HBI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no correlation (P value not reported)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gomes Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gomes Score (endoscopic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.76 (P &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laharie Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.154 (P = 0.344)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laharie Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No correlation but no numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naini and Cortina Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>likelihood of IBD/</p> <p>histopathologic</p> <p>support for IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Positive predictive value</p> <p>for ileal involvement by IBD:</p> <p>ileal cut‐off score of 5: 88%</p> <p>ileal scores of 3 or 4: 53%</p> <p>ileal scores of 2 or less: 19%</p> <p>Positive predictive value</p> <p>for colonic involvement by IBD:</p> <p>colonic cut‐off score of 9: 92%</p> <p>colonic scores of 4 to 8: 52%</p> <p>colonic scores of 3 or less: 8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regueiro Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rutgeerts Score (endoscopic postoperative disease activity score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.73 (P &lt; 0.0001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sipponen Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD (ileal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileal GHAS: r = 0.779 (P &lt; 0.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sipponen Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD (colonic ‐ the sum of the scores for 4 colonic segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonic GHAS: r = 0.759 (P &lt; 0.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ward Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognosis of Crohn's disease as defined by 4 groups of clinical outcomes:</p> <p>group 1 (good): remaining asymptomatic at latest review</p> <p>group 2 (moderate): continued symptomatic activity together with evidence on sigmoidoscopy of continued inflammation </p> <p>group 3 (colectomy): disease process of severity sufficient to require colectomy but who subsequently remained in good general health </p> <p>group 4 (death): died as a direct result of the severity of the granulomatous colitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Score of four clinical groups for first biopsies (n = 27):</p> <p>group 1: 3.0 (difference to group 4: P &lt; 0.05)</p> <p>group 2: 3.2 (difference to group 4: P &lt; 0.05)</p> <p>group 3: 3.5</p> <p>group 4: 4.9</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CDAI, Crohn's Disease Activity Score; CDEIS, Crohn's Disease Endoscopic Index of Severity; HBI, Harvey‐Bradshaw Index; IBDQ, Inflammatory Bowel Disease Questionnaire; SES‐CD, Simple Endoscopic Score for Crohn's Disease </p> </div> </div> <p><b>Responsiveness</b> </p> <p>Responsiveness data regarding seven histological scoring indices is described in <a href="#CD012351-tbl-0008">Table 8</a>. After subjects were administered a treatment of known efficacy, there was a statistically significant change score observed with the GHAS (<a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>), the CGHAS and IGHAS (<a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a>), the Agnholt Score (<a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a>), the AHS (<a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a>) and the Dieleman Score (<a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a>). </p> <div class="table" id="CD012351-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Responsiveness</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Correlation with Responsiveness Meaure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agnholt Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infliximab 5 mg/kg body weight at week 0, 2 and 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median decrease:</p> <p>from 2.0 (interquartile range (IQR) = 1‐3) to 1.0 (IQR 0‐3), P = 0.011</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0002" title="BaertF J , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22‐8. ">Baert 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GHAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infliximab (5, 10 or 20 mg/kg body weight) as a single infusion or placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean decrease in colonic specimens:</p> <p>infliximab arm (n = 11): from 8.3 to 3.4, P = ?</p> <p>placebo arm (n = 2): from 6.5 to 6, P = ?</p> <p>Mean decrease in ileal specimens:</p> <p>infliximab arm (n = 6): from 8.2 to 2.3, P = ?</p> <p>placebo arm (n = 4): from 6.8 to 6.3, P = ?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GHAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infliximab (5, 10 or 20 mg/kg body weight) as a single infusion or placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean decrease in colonic specimens:</p> <p>infliximab arm (n = 7): from 8.8+/‐1.7 (range, 2‐10) to 2.7+/‐1.7 (range, 0‐8), P &lt; 0.01 </p> <p>placebo arm (n = 4): from 11.0+/‐2.3 to 9.0+/‐1.9, P &gt; 0.05</p> <p>Mean decrease in ileal specimens:</p> <p>infliximab arm (n = 4): from 7.7+/‐2.3 (range, 4‐12) to 3.3+/‐2.0 (range, 0‐7), P &lt; 0.01 </p> <p>placebo arm (n = 3): from 9.2+/‐2.4 to 8.7+/‐3.1, P &gt; 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGHAS (colonic GHAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIngle dose/episodic group (5 mg/kg infliximab at week 0, placebo at week 2, 6 and every 8 weeks with possible episodic infliximab re‐treatment in case of worsening) </p> <p>Combined maintenance/episodic group (5 mg/kg at week 0, 2 and 6, after that every 8 weeks 5 or 10 mg/kg with possible episodic re‐treatment in case of worsening) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean decrease in single dose/episodic group:</p> <p>from 10 (week 0, n = 15) to 4 (week 10, n = 15, P &lt; 0.05) and 5 (week 54, n = 10, P &gt; 0.05) </p> <p>Mean decrease in the combined maintenance/episodic group:</p> <p>from 9 (week 0, n = 25) to 2 (week 10, n = 25, P &lt; 0.001) and 2 (week 54, n = 18, P &lt; 0.001) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IGHAS (ileal GHAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIngle dose/episodic group (5 mg/kg infliximab at week 0, placebo at week 2, 6 and every 8 weeks with possible episodic infliximab re‐treatment in case of worsening) </p> <p>Combined maintenance/episodic group (5 mg/kg at week 0, 2 and 6, after that every 8 weeks 5 or 10 mg/kg with possible episodic re‐treatment in case of worsening) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean decrease in single dose/episodic group:</p> <p>from 1 (week 0, n = 10) to 1 (week 10, n = 10, P &gt; 0.05) and 2 (week 54, n = 9, P &gt; 0.05) </p> <p>Mean decrease in the combined maintenance/episodic group:</p> <p>from 2 (week 0, n = 19) to 0 (week 10, n = 19, P &lt; 0.001) and 0 (week 54, n = 14, P &gt; 0.05) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AHS (average GHAS per intestinal segment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine 2‐2.5 mg/kg a day (n = 38)</p> <p>or budesonide 6‐9 mg/day (n = 39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine arm:</p> <p>from 5.92+/‐1.7 at baseline to 2.92+/‐1.93 at study termination (intention to treat analysis: P &lt; 0.01) </p> <p>Budesonide arm:</p> <p>from 5.72+/‐1.63 at baseline to 6.01+/‐1.72 at study termination (ITT analysis: P = 0.31) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dieleman Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naltrexone 4.5 mg orally or placebo for 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naltrexone arm:</p> <p>from 16 to 6 (P = 0.016)</p> <p>Placebo arm:</p> <p>18 before and after treatment (N.S.)</p> <p>When former placebo‐treated patients were subsequently administered naltrexone for 12 week in extended open‐label study a significant improvement in histology was observed (P = 0.006, other data not reported) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saverymuttu</p> <p>Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Enteral nutrition Elentel (1 kcal/mL, 760 mOsm/L). Adaptation phase (concentration gradually increased from 1/3 to full strength) 7 days and maintenance phase (at the full strength) for 4 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>terminal ileum</p> <p>Before treatment (n = 28):</p> <p>grade 0: 2 (7%), grade 1: 8 (29%), grade 2: 11 (39%), grade 3: 77 (25%)</p> <p>After treatment (n = 28):</p> <p>grade 0: 7 (25%), grade 1: 8 (29%), grade 2: 10 (36%), grade 3: 3 (11%)</p> <p>colon</p> <p>Before treatment (n = 28):</p> <p>grade 0: 8 (29%), grade 1: 8 (29%), grade 2: 7 (25%), grade 3: 5 (18%)</p> <p>After treatment (n = 28):</p> <p>grade 0: 12 (43%), grade 1: 8 (29%), grade 2: 6 (21%), grade 3: 2 (7%)</p> </td> </tr> </tbody> </table> </div> <p>Although <a href="./references#CD012351-bbs2-0002" title="BaertF J , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22‐8. ">Baert 1999</a> and <a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a> observed decreases in the GHAS and Saverymuttu Score, respectively, following a treatment of known efficacy, testing for statistical significance was not performed in these studies. </p> <p><b>Feasibility</b> </p> <p>One of the included studies evaluated feasibility (<a href="#CD012351-tbl-0009">Table 9</a>). In the application phase of the development of the Naini and Coritna Score, pathologists rated the novel index as being simple to use and easily completed in less than 30 seconds (Naini 2012). </p> <div class="table" id="CD012351-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Feasibility</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Feasibility Scoring</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naini and Cortina score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The scoring worksheet was easy to use, could be appropriately applied and was easily completed in less than 30 seconds for each patient </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012351-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012351-sec-0048"></div> <section id="CD012351-sec-0049"> <h3 class="title" id="CD012351-sec-0049">Summary of main results</h3> <p>Sixteen reports of 14 studies describing 13 numerical histological indices fulfilled the inclusion criteria. Inter‐rater reliability was assessed in one study (Naini 2012). For scoring ileitis and colitis with the Naini and Cortina Score, ICCs ranged from r = 0.94 to r = 0.96. With regard to methodological quality, the study was rated as 'good'. </p> <p>With respect to validity, correlation estimates between various histological scoring systems and Crohn's disease activity as measured by objective markers of inflammation (i.e. CRP, ESR, fecal calprotectin and lactoferrin), endoscopic disease activity scores, clinical disease activity scores and quality of life measures were reported. For criterion validity, estimates of correlation ranged from r = 0.25 to r = 0.56 (<a href="#CD012351-tbl-0006">Table 6</a>).The estimates of correlation of histological scoring indices with endoscopic disease activity scores ranged from no correlation (<a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a>) to 'substantial' (r = 0.779) (<a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a>). With respect to construct validity, the estimates of correlation between the histologic scoring indices and the clinical disease activity or quality of life measures ranged from no correlation to 0.78 (<a href="#CD012351-tbl-0007">Table 7</a>). It should be noted that no more than one study assessed each scoring index for validity. </p> <p>Responsiveness data were available in seven studies. After subjects were administered a treatment of known efficacy, statistically significant changes in index scores were demonstrated in five studies (<a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a>; <a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a>; <a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a>; <a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a>). In two studies (<a href="./references#CD012351-bbs2-0002" title="BaertF J , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22‐8. ">Baert 1999</a>; <a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a>), the histologic score decreased after a treatment of known efficacy was administered, but testing for statistical significance was not performed. </p> <p>Feasibility was assessed by one study (Naini 2012). The Naini and Cortina Score was shown to be simple to use and feasible for every given case. </p> </section> <section id="CD012351-sec-0050"> <h3 class="title" id="CD012351-sec-0050">Overall completeness and applicability of evidence</h3> <p>One study specifically aimed to develop and validate a histological scoring index (Naini 2012). However, the Naini and Corina Score is not specific to Crohn's disease and was not developed to assess histological disease activity, but rather to diagnose IBD. </p> <p>None of the histological disease activity indices identified in the current review including the extensively used GHAS have been formally validated, and many of the validation studies were of poor methodological quality. </p> </section> <section id="CD012351-sec-0051"> <h3 class="title" id="CD012351-sec-0051">Quality of the evidence</h3> <p>Four operating properties were assessed by the included studies: reliability, hypothesis testing (a facet of construct validity), criterion validity and responsiveness (<a href="#CD012351-tbl-0004">Table 4</a>). The single study that examined index reliability was rated as 'poor' with regard to methodological quality. For hypothesis testing, there were five evaluations conducted. Three of these studies were rated as 'poor' and two were rated as 'fair'. Eight studies reported on criterion validity, with five of these studies being rated as 'poor', two rated as 'fair' and one rated as 'good'. Finally, seven studies measured responsiveness. Six of these studies were rated as 'poor' methodological quality and one was rated as 'fair'. The Nainia and Cortina Score was assessed for feasibility, and found to be easily administered. Details on the interpretability and generalisability of the included studies are listed in <a href="#CD012351-tbl-0004">Table 4</a>. </p> </section> <section id="CD012351-sec-0052"> <h3 class="title" id="CD012351-sec-0052">Potential biases in the review process</h3> <p>It should be noted that stepwise histological scoring indices were excluded from this review. Most stepwise indices include the same or similar items and are thus subject to considerable overlap. While such scoring indices are easy to use, it is likely that they are less responsive to clinically meaningful changes in disease activity (<a href="./references#CD012351-bbs2-0110" title="MojtahedA , KhannaR , SandbornWJ , DʼHaensGR , FeaganBG , ShackeltonLM , et al. Assessment of histologic disease activity in Crohn's disease: a systematic review. Inflamm Bowel Diseases2014;20(11):2092‐103. ">Mojtahed 2014</a>). However, it should be acknowledged that these indices exist and that these indices are not represented in the current review. </p> <p>It is also worth noting that numerous issues regarding biopsy collection and processing remain. Biopsy specimens in the included studies were procured according to various protocols. More specifically, different numbers of biopsies were taken at different locations. In most studies, biopsy specimens were taken from the most macroscopically inflamed areas. This strategy seems sensible, but there is no evidence to support that this is the best method for procuring biopsy specimens. Efforts should be made to standardise and optimise biopsy sampling protocols while taking the anatomic heterogeneity of Crohn's disease into account to reduce sampling error. At present there is no uniform methodology on how to handle biopsy specimens (e.g. type of forceps, orientation of the sample before fixation, duration of fixation, or sectioning) (<a href="./references#CD012351-bbs2-0109" title="LangnerC , MagroF , DriessenA , EnsariA , MantzarisGJ , VillanacciV , et al. The histopathological approach to inflammatory bowel disease: a practice guide. Virchows Archiv: an International Journal of Pathology2014;464(5):511‐27. ">Langner 2014</a>). Good sample quality is necessary for assessment of the sections (<a href="./references#CD012351-bbs2-0104" title="GeboesK , RiddellR , OstA , JensfeltB , PerssonT , LöfbergR . A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut2000;47(3):404‐9. ">Geboes 2000</a>; <a href="./references#CD012351-bbs2-0112" title="MosliMH , FeaganBG , ZouG , SandbornWJ , D'HaensG , KhannaR , et al. Development and validation of a histological index for UC. Gut2017;66(1):50‐8. ">Mosli 2017</a>), but it is not clear whether quality checks and exclusion of poor quality specimens was performed. Furthermore, specific training of pathologists on how to use scoring systems might be needed (<a href="./references#CD012351-bbs2-0104" title="GeboesK , RiddellR , OstA , JensfeltB , PerssonT , LöfbergR . A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut2000;47(3):404‐9. ">Geboes 2000</a>; <a href="./references#CD012351-bbs2-0112" title="MosliMH , FeaganBG , ZouG , SandbornWJ , D'HaensG , KhannaR , et al. Development and validation of a histological index for UC. Gut2017;66(1):50‐8. ">Mosli 2017</a>). Most of these issues were not assessed in the studies included in this systemic review. </p> </section> <section id="CD012351-sec-0053"> <h3 class="title" id="CD012351-sec-0053">Agreements and disagreements with other studies or reviews</h3> <p>Our review is in agreement with another systemic review on histological disease activity indices in Crohn's disease (<a href="./references#CD012351-bbs2-0110" title="MojtahedA , KhannaR , SandbornWJ , DʼHaensGR , FeaganBG , ShackeltonLM , et al. Assessment of histologic disease activity in Crohn's disease: a systematic review. Inflamm Bowel Diseases2014;20(11):2092‐103. ">Mojtahed 2014</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012351-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/media/CDSR/CD012351/urn:x-wiley:14651858:media:CD012351:CD012351-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/media/CDSR/CD012351/image_t/tCD012351-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012351-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012351.pub2/media/CDSR/CD012351/image_n/nCD012351-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/media/CDSR/CD012351/image_n/nCD012351-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012351-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/media/CDSR/CD012351/urn:x-wiley:14651858:media:CD012351:CD012351-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/media/CDSR/CD012351/image_t/tCD012351-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012351-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012351.pub2/media/CDSR/CD012351/image_n/nCD012351-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/media/CDSR/CD012351/image_n/nCD012351-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD012351-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Indices that have been fully or partially validated</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Histologic index evaluated</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>GHAS or modification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agnholt Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global Histological Activity Score (GHAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drews Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonic Global Histological Activity Score (CGHAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileal Global Histological Activity Score (IGHAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gomes Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laharie Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Average Histologic Score (AHS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naini and Cortina Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regueiro Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sipponen Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dieleman Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ward Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Savermuttu Index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Indices that have been fully or partially validated</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012351-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Scoring Index Cut‐offs</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cut‐off</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agnholt Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic inflammatory activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0002" title="BaertF J , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22‐8. ">Baert 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GHAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GHAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drews Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic inflammatory activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stage 0 (score 0): no increase in inflammation</p> <p>stage 1 (1‐3): chronic, non‐active inflammation</p> <p>stage 2 (4‐6): mild active inflammation</p> <p>stage 3 (7‐9): moderate active inflammation</p> <p>stage 4 (10‐14): severe active inflammation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gobes Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gomes Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported. Maximum score: 24.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laharie Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported. Score ranges from 1 (no activity) to 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AHS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naini and Cortina Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>likelihood of IBD/</p> <p>histopathologic</p> <p>support for IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Probability of chronic ileitis (max. score = 10)</p> <p>low 0‐2</p> <p>moderate 3‐4</p> <p>high 5‐10</p> <p>Probability of chronic colitis (max. score =17)</p> <p>low 0‐3</p> <p>moderate 4‐8</p> <p>high 9‐17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regueiro Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>inactive: 0</p> <p>mildly active: 1‐5</p> <p>moderately active: 6‐10</p> <p>severely active: 11‐14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sipponen Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dieleman Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic inflammatory activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ward Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prognosis of Crohn's disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported. Maximum score 10.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saverymuttu Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>histologic disease activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total score of 4 items:</p> <p>0‐1 ‐ Grade 0 (none inflammation)</p> <p>2‐4 ‐ Grade 1 (mild inflammation)</p> <p>5‐8 ‐ Grade 2 (moderate inflammation)</p> <p>9‐12 ‐ Grade 3 (severe inflammation)</p> <p>Histologic healing was defined as grade of 0</p> <p>Histologic improvement (including healing).was defined</p> <p>as a decrease of at least 1 grade</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Scoring Index Cut‐offs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012351-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of operating properties of histologic scoring indices for Crohn's disease</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scoring index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Reliability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Responsiveness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Feasibility</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Content validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criterion validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Construct validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intra‐rater</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inter‐rater</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Test‐retest</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Internal consistency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AHS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGHAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dieleman Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GHAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+/‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drews Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gomes Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+/‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saverymuttu Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ward Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+/‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IGHAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+/‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sipponen Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laharie Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regueiro Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agnholt Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naini and Cortina Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>+ positive rating</p> <p>? no information or indeterminate rating</p> <p>‐ Negative rating</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of operating properties of histologic scoring indices for Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012351-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">The methodological quality of histologic index measurement properties as described in the original development articles (COSMIN checklist)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>B</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>C</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>D</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>E</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>F</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>G</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>H</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>I</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>J</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Internal consistency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reliability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measurement</b> </p> <p><b>error</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Construct validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Factor analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypothesis</b> </p> <p><b>testing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross‐cultural validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criterion</b> </p> <p><b>validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Responsiveness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interpretability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Generlisability</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>pre‐treatment 2.0 (IQR 1‐3)</p> <p>post‐treatment 1.0 (IQR 0‐3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) age (range): female/male: 33 (27‐50), 40 (18‐67)</p> <p>2) female/male: 14/12</p> <p>3) disease characteristics and duration of treatment:</p> <p>see table Characteristics of included studies</p> <p>4) setting: prospective single‐centre trial at Aarhus university hospital</p> <p>5) country: Denmark</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0002" title="BaertF J , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22‐8. ">Baert 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>A) Colonic</p> <p>Mean decrease in colonic specimens:</p> <p>infliximab arm (n = 11): from 8.3 (1‐12) to 3.4 (0‐7)</p> <p>placebo arm (n = 2): from 6.5 (6‐7) to 6 (5‐7)</p> <p>B) Ileal:</p> <p>Mean decrease in ileal specimens:</p> <p>infliximab arm (n = 6): from 8.2 (2‐12) to 2.3 (0‐6)</p> <p>placebo arm (n = 4): from 6.8 (1‐10) to 6.3 (4‐10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Age (range): placebo arm 32.6 (25‐41), infliximab arm 32.07 (20‐47)</p> <p>2) Female/male: 12/6</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: Single‐centre, placebo‐controlled, randomised trial at University hospital Gasthuisberg, Leuven </p> <p>5) country: Belgium</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>A) Colonic</p> <p>infliximab arm (n = 7): before 8.8+/‐1.7 (range, 2‐10) and after infusion of infliximab 2.7+/‐1.7 (range, 0‐8) </p> <p>placebo arm (n = 4): before 11.0+/‐2.3 and after infusion of placebo 9.0+/‐1.9</p> <p>B) Ileal:</p> <p>infliximab arm (n = 4): before 7.7+/‐2.3 (range, 4‐12) and after infusion of infliximab 3.3+/‐2.0 (range, 0‐7) </p> <p>placebo arm (n = 3): before 9.2+/‐2.4 and after infusion of placebo 8.7+/‐3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>data for the whole cohort ‐ not described for patients with histologic assessment only: </p> <p>1) mean age: placebo arm 34.4 (+/‐ 9.8), infliximab arm 31.4 (+/‐ 7.1)</p> <p>2) Female/male: 18/12</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: international multi‐centre, randomised, placebo‐controlled trial, biopsies specimens taken only in one centre (University hospital Gasthuisberg, Leuven) </p> <p>5) countries: biopsies only in Belgium</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores (n = 32):</p> <p>stage 0: 8 (25%)</p> <p>stage 1: 5 (16%)</p> <p>stage 2: 10 (31%)</p> <p>stage 3: 3 (9%)</p> <p>stage 4: 6 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Mean age (range): 38.75 (17‐71)</p> <p>2) Female/male: 18/14</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: retrospective analysis from a single centre</p> <p>5) countries: Germany</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fair (CGHAS)</p> <p>and poor (IGHAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fair (CGHAS)</p> <p>and poor (IGHAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>A) Median CGHAS</p> <p>SIngle dose/episodic group:</p> <p>10 (week 0), 4 (week 10) and 5 (week 54)</p> <p>Combined maintenance/episodic group:</p> <p>9 (week 0), 2 (week 10) and 2 (week 54)</p> <p>B) Median IGHAS</p> <p>SIngle dose/episodic group:</p> <p>1 (week 0), 1 (week 10) and 2 (week 54)</p> <p>Combined maintenance/episodic group:</p> <p>2 (week 0), 0 (week 10) and 0 (week 54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Median age: 30</p> <p>2) Female/male: 28/20</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: international multi‐centre, randomised, controlled trial in European centres</p> <p>5) countries: European (not reported which countries)</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of histologic scores:</p> <p>range 0‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Age: not reported</p> <p>2) Female/male: not reported</p> <p>3) disease characteristics and duration of treatment: not reported</p> <p>4) setting: prospective, single centre trial</p> <p>5) countries: USA</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>methotrexate arm (n = 12): median 2.5, range 1‐12</p> <p>azathioprine arm (n = 14): median 3, range 0‐11</p> <p>infliximab arm (n = 14): median 3.5, range 0‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>data for the whole cohort ‐ not described for patients with histologic assessment only: </p> <p>1) Median age (range): methotrexate arm (n = 18) 40 (21‐56), azathioprine arm (n = 18) 48 (21‐89), infliximab arm (n = 15) 46 (30‐79) </p> <p>2) Female/male: 38/13</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: prospective single‐centre study at the Haut‐Leveque hospital</p> <p>5) country: France</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>Azathioprine arm: from 5.92+/‐1.7 at baseline to 2.92+/‐1.93 at study termination</p> <p>Budesonide arm:</p> <p>from 5.72+/‐1.63 at baseline to 6.01+/‐1.72 at study termination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Median age (range): azathioprine arm (n = 38) 34.3 (19‐59), budesonide arm (n = 39) 34.5 (19‐62) </p> <p>2) Female/male: 43/34</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: prospective single‐centre, randomised, controlled study in Athens</p> <p>5) country: Greece</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) the distribution of scores (total and IBD):</p> <p>Ileal scores (max. of 10) ranged from 0 to 8</p> <p>Colonic scores (max. of 17) ranged from 0 to 13</p> <p>2) scores for relevant subgroups</p> <p>(ileal score: mean (SD), colonic score: mean (SD))</p> <p>ulcerative colitis 0,65 (1.5), 9.4 (2.8)</p> <p>Crohn's disease 3.5 (2.4), 5.2 (3.6)</p> <p>IBD unclassified 0, 5.9 (3.7)</p> <p>non‐IBD chronic ileocolitis 0.5 (0.7), 3.4 (2.9)</p> <p>nonspecific chronic ileocolitis 3.0 (3.5), 4.5 (1.7)</p> <p>no chronic ileocolitis 0.3 (0.8),1.0 (1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) mean age (range) for subgroups:</p> <p>ulcerative colitis 26 (11‐43), Crohn's disease 32 (13‐57),</p> <p>IBD unclassified 34 (17‐51), non‐IBD chronic</p> <p>ileocolitis 53 (25‐81), nonspecific chronic</p> <p>ileocolitis 53 (43‐63), no chronic ileocolitis 47 (15‐89)</p> <p>2) male/female: 59/105</p> <p>3) disease characteristics and duration of treatment:</p> <p>see table Characteristics of included studies</p> <p>4) setting: study with 2 retrospective phases (calibration and validation) and a prospective phase (application) in a single centre </p> <p>5) country: USA</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>score 0‐3: 12 patients</p> <p>score 4‐6: 3 patients</p> <p>score 7‐14: 9 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Median age: infliximab arm 43, placebo arm 32</p> <p>2) Female/male: 8/16</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: randomised, two‐armed, double blinded, placebo‐controlled trial at the University of Pittsburgh Medical Centre </p> <p>5) country: USA</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>in ileocolonic or colonic disease, median total histology score was 15 (range 0‐45), ileal histology score 4 (0‐11) and histology score of the colon 13 (0‐38). </p> <p>In the ileal disease, ileal histology score was 6 (0‐10).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Median age (range): 33 (19‐70)</p> <p>2) Female/male: 31/30</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: prospective single‐center study</p> <p>5) country: Finland</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>Naltrexone arm (n = 18):</p> <p>from 16 before treatment to 6 after treatment</p> <p>Placebo arm (n = 16):</p> <p>18 before and after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Mean age (range): naltrexone arm 40.5 (21‐60), placebo arm 44.8 (26‐67)</p> <p>2) Female %: naltrexone arm 64.7%, placebo arm 62.5 %</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: prospective, double blind, randomised placebo‐controlled trial at a single centre </p> <p>5) countries: USA</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores (n = 27):</p> <p>group 1: 3.0 (0.7‐6)</p> <p>group 2: 3.2 (0.7‐5.3)</p> <p>group 3: 3.5 (1.7‐6.7)</p> <p>group 4: 4.9 (3.3‐7.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Mean age at onset (range): group Good 34.7 (19‐68), group Moderate 22.4 (17‐36), group Colectomy 39.1 (18‐49), group Death 38.5 (13‐62) </p> <p>2) Female/male: 12/15</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: retrospective study at a single centre</p> <p>5) countries: Scotland, United Kingdom</p> <p>6) language: not relevant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>the distribution of scores:</p> <p>A) terminal ileum</p> <p>Before treatment (n = 28):</p> <p>grade 0: 2 (7%), grade 1: 8 (29%), grade 2: 11 (39%), grade 3: 77 (25%)</p> <p>After treatment (n = 28):</p> <p>grade 0: 7 (25%), grade 1: 8 (29%), grade 2: 10 (36%), grade 3: 3 (11%)</p> <p>B) colon</p> <p>Before treatment (n = 28):</p> <p>grade 0: 8 (29%), grade 1: 8 (29%), grade 2: 7 (25%), grade 3: 5 (18%)</p> <p>After treatment (n = 28):</p> <p>grade 0: 12 (43%), grade 1: 8 (29%), grade 2: 6 (21%), grade 3: 2 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Median age (interquartile range): 28 (22‐36)</p> <p>2) Female/male:12/16</p> <p>3) disease characteristics and duration of treatment: see table Characteristics of included studies </p> <p>4) setting: prospective, single centre, pilot trial</p> <p>5) countries: Japan</p> <p>6) language: not relevant</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">The methodological quality of histologic index measurement properties as described in the original development articles (COSMIN checklist)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012351-tbl-0005"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Reliability</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inter‐rater Kappa</b> </p> <p><b>(between raters)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inter‐rater ICC</b> </p> <p><b>(between raters)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intra‐rater</b> </p> <p><b>Kappa</b> </p> <p><b>(within rater)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intra‐rater ICC</b> </p> <p><b>(within rater)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Internal Consistency</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naini and Cortina score</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phase I</p> <p>(before score modification):</p> <p>Ileitis ICC: 0.96</p> <p>Colitis ICC: 0.95</p> <p>Phase II</p> <p>Ileitis ICC: 0.94</p> <p>Colitis ICC: 0.94</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Abbreviations: ICC, interclass correlation coefficient</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Reliability</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012351-tbl-0006"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Criterion Validity</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Correlation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histology score by Gomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.34 (P valued not stated)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histology score by Gomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.25 (P valued not stated)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileal GHAS (modified GHAS by Sipponen)</p> <p>Colonic GHAS (modified GHAS by Sipponen)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Faecal calprotectin</p> <p>(quantitative enzyme immunoassay, PhiCal Test, Calpro AS, Oslo, Norway, values &lt; 100 mcg/g stoll considered normal) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileal GHAS: r = 0.311 (P valued not stated)</p> <p>Colonic GHAS: r = 0.563 (P &lt; 0.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileal GHAS (modified GHAS by Sipponen)</p> <p>Colonic GHAS (modified GHAS by Sipponen)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Faecal lactoferrin</p> <p>(quantitative enzyme immunoassay, IBD‐SCAN, Inverness Medical, Princeton, NJ, USA, Techlab, Blacksburg, VA, USA, values &lt; 7.25 mcg/g stoll considered normal) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileal GHAS: r = 0.291 (P valued not stated)</p> <p>Colonic GHAS: r = 0.543 (P &lt; 0.01)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Criterion Validity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012351-tbl-0007"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Construct Validity</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Correlation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agnholt Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>week 0: r = 0.5 (P = 0.019)</p> <p>week 8: r = 0.6 (P = 0.002)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0004" title="DrewsBH , BarthTF , HanleMM , AkinliAS , MasonRA , MucheR , et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. European Radiology2009;19(6):1379‐86. ">Drews 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drews Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no significant association (P = 0.2482)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geboes Score (colonic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>change from week 0 to week 10: r = 0.43 (P = 0.006, n = 40)</p> <p>change from week 0 to week 54: r = 0.10 (P = 0.700, n = 17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geboes Score (ileal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>change from week 0 to week 10: r = 0.27 (P = 0.155, n = 29)</p> <p>change from week 0 to week 54: r = 0.68 (P = 0.001, n = 13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geboes Score (colonic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBDQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>change from week 0 to week 10: r = ‐0.33 (P = 0.037, n = 40)</p> <p>change from week 0 to week 54: r = ‐0.04 (P = 0.873, n = 17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geboes Score (ileal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBDQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>change from week 0 to week 10: r = ‐0.29 (P = 0.132, n=29)</p> <p>change from week 0 to week 54: r = ‐0.35 (P = 0.246, n=13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geboes Score (colonic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>at week 0: r = 0.56 (P &lt; 0.001, n = 45)</p> <p>change from week 0 to week 10: r = 0.52 (P = 0.001, n = 40)</p> <p>change from week 0 to week 54: r = 0.40 (P = 0.110, n = 17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geboes Score (ileal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>change from week 0 to week 10: r = 0.05 (P = 0.78, n = 29)</p> <p>change from week 0 to week 54: r = 0.42 (P = 0.153, n = 13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gomes Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HBI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no correlation (P value not reported)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0006" title="GomesP , du BoulayC , SmithC L , HoldstockG . Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut1986;27(1):92‐5. ">Gomes 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gomes Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gomes Score (endoscopic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.76 (P &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laharie Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.154 (P = 0.344)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0007" title="LaharieD , ReffetA , BelleanneeG , ChabrunE , SubtilC , RazaireS , et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics2011;33(6):714‐21. ">Laharie 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laharie Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No correlation but no numbers reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naini and Cortina Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>likelihood of IBD/</p> <p>histopathologic</p> <p>support for IBD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Positive predictive value</p> <p>for ileal involvement by IBD:</p> <p>ileal cut‐off score of 5: 88%</p> <p>ileal scores of 3 or 4: 53%</p> <p>ileal scores of 2 or less: 19%</p> <p>Positive predictive value</p> <p>for colonic involvement by IBD:</p> <p>colonic cut‐off score of 9: 92%</p> <p>colonic scores of 4 to 8: 52%</p> <p>colonic scores of 3 or less: 8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0010" title="RegueiroM , Palma‐DiazM , El‐HachemS , KipKE , SchrautWH , HarrisonJ , et al. Correlation of histologic and endoscopic scores for evaluation of Crohn's disease recurrence after ileal resection and infliximab therapy. Gastroenterology2010;138(5):S‐358. RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PesciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441‐50. ">Regueiro 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regueiro Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rutgeerts Score (endoscopic postoperative disease activity score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.73 (P &lt; 0.0001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sipponen Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD (ileal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileal GHAS: r = 0.779 (P &lt; 0.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0011" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sipponen Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD (colonic ‐ the sum of the scores for 4 colonic segments)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonic GHAS: r = 0.759 (P &lt; 0.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0013" title="WardM , WebbJN . Rectal biopsy as a prognostic guide in Crohn's colitis. Journal of Clinical Pathology1977;30(2):126‐31. ">Ward 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ward Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognosis of Crohn's disease as defined by 4 groups of clinical outcomes:</p> <p>group 1 (good): remaining asymptomatic at latest review</p> <p>group 2 (moderate): continued symptomatic activity together with evidence on sigmoidoscopy of continued inflammation </p> <p>group 3 (colectomy): disease process of severity sufficient to require colectomy but who subsequently remained in good general health </p> <p>group 4 (death): died as a direct result of the severity of the granulomatous colitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Score of four clinical groups for first biopsies (n = 27):</p> <p>group 1: 3.0 (difference to group 4: P &lt; 0.05)</p> <p>group 2: 3.2 (difference to group 4: P &lt; 0.05)</p> <p>group 3: 3.5</p> <p>group 4: 4.9</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Abbreviations: CDAI, Crohn's Disease Activity Score; CDEIS, Crohn's Disease Endoscopic Index of Severity; HBI, Harvey‐Bradshaw Index; IBDQ, Inflammatory Bowel Disease Questionnaire; SES‐CD, Simple Endoscopic Score for Crohn's Disease </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Construct Validity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012351-tbl-0008"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Responsiveness</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Correlation with Responsiveness Meaure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0001" title="AgnholtJ , DahlerupJF , BuntzenS , TottrupA , NielsenSL , LundorfE . Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Alimentary Pharmacology and Therapeutics2003;17(5):703‐10. ">Agnholt 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agnholt Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infliximab 5 mg/kg body weight at week 0, 2 and 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median decrease:</p> <p>from 2.0 (interquartile range (IQR) = 1‐3) to 1.0 (IQR 0‐3), P = 0.011</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0002" title="BaertF J , D'HaensGR , PeetersM , HieleMI , SchaibleTF , ShealyD , et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology1999;116(1):22‐8. ">Baert 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GHAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infliximab (5, 10 or 20 mg/kg body weight) as a single infusion or placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean decrease in colonic specimens:</p> <p>infliximab arm (n = 11): from 8.3 to 3.4, P = ?</p> <p>placebo arm (n = 2): from 6.5 to 6, P = ?</p> <p>Mean decrease in ileal specimens:</p> <p>infliximab arm (n = 6): from 8.2 to 2.3, P = ?</p> <p>placebo arm (n = 4): from 6.8 to 6.3, P = ?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0003" title="D'HaensG , DeventerS , HogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GHAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infliximab (5, 10 or 20 mg/kg body weight) as a single infusion or placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean decrease in colonic specimens:</p> <p>infliximab arm (n = 7): from 8.8+/‐1.7 (range, 2‐10) to 2.7+/‐1.7 (range, 0‐8), P &lt; 0.01 </p> <p>placebo arm (n = 4): from 11.0+/‐2.3 to 9.0+/‐1.9, P &gt; 0.05</p> <p>Mean decrease in ileal specimens:</p> <p>infliximab arm (n = 4): from 7.7+/‐2.3 (range, 4‐12) to 3.3+/‐2.0 (range, 0‐7), P &lt; 0.01 </p> <p>placebo arm (n = 3): from 9.2+/‐2.4 to 8.7+/‐3.1, P &gt; 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGHAS (colonic GHAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIngle dose/episodic group (5 mg/kg infliximab at week 0, placebo at week 2, 6 and every 8 weeks with possible episodic infliximab re‐treatment in case of worsening) </p> <p>Combined maintenance/episodic group (5 mg/kg at week 0, 2 and 6, after that every 8 weeks 5 or 10 mg/kg with possible episodic re‐treatment in case of worsening) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean decrease in single dose/episodic group:</p> <p>from 10 (week 0, n = 15) to 4 (week 10, n = 15, P &lt; 0.05) and 5 (week 54, n = 10, P &gt; 0.05) </p> <p>Mean decrease in the combined maintenance/episodic group:</p> <p>from 9 (week 0, n = 25) to 2 (week 10, n = 25, P &lt; 0.001) and 2 (week 54, n = 18, P &lt; 0.001) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0005" title="GeboesK , RutgeertsP , OpdenakkerG , OlsonA , PatelK , WagnerCL , et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion2005;21(11):1741‐54. ">Geboes 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IGHAS (ileal GHAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIngle dose/episodic group (5 mg/kg infliximab at week 0, placebo at week 2, 6 and every 8 weeks with possible episodic infliximab re‐treatment in case of worsening) </p> <p>Combined maintenance/episodic group (5 mg/kg at week 0, 2 and 6, after that every 8 weeks 5 or 10 mg/kg with possible episodic re‐treatment in case of worsening) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean decrease in single dose/episodic group:</p> <p>from 1 (week 0, n = 10) to 1 (week 10, n = 10, P &gt; 0.05) and 2 (week 54, n = 9, P &gt; 0.05) </p> <p>Mean decrease in the combined maintenance/episodic group:</p> <p>from 2 (week 0, n = 19) to 0 (week 10, n = 19, P &lt; 0.001) and 0 (week 54, n = 14, P &gt; 0.05) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0008" title="MantzarisG J , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AHS (average GHAS per intestinal segment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine 2‐2.5 mg/kg a day (n = 38)</p> <p>or budesonide 6‐9 mg/day (n = 39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine arm:</p> <p>from 5.92+/‐1.7 at baseline to 2.92+/‐1.93 at study termination (intention to treat analysis: P &lt; 0.01) </p> <p>Budesonide arm:</p> <p>from 5.72+/‐1.63 at baseline to 6.01+/‐1.72 at study termination (ITT analysis: P = 0.31) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0012" title="SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: A placebo‐controlled trial. Gastroenterology2010;138(5):S‐85, S‐86. SmithJP , BingamanSI , RuggieroF , MaugerDT , MukherjeeA , McGovernCO , et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Digestive Diseases and Sciences2011;56(7):2088‐97. ">Smith 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dieleman Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naltrexone 4.5 mg orally or placebo for 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naltrexone arm:</p> <p>from 16 to 6 (P = 0.016)</p> <p>Placebo arm:</p> <p>18 before and after treatment (N.S.)</p> <p>When former placebo‐treated patients were subsequently administered naltrexone for 12 week in extended open‐label study a significant improvement in histology was observed (P = 0.006, other data not reported) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0014" title="YamamotoT , NakahigashiM , UmegaeS , KitagawaT , MatsumotoK . Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflammatory Bowel Diseases2005;11(6):580‐8. ">Yamamoto 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saverymuttu</p> <p>Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Enteral nutrition Elentel (1 kcal/mL, 760 mOsm/L). Adaptation phase (concentration gradually increased from 1/3 to full strength) 7 days and maintenance phase (at the full strength) for 4 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>terminal ileum</p> <p>Before treatment (n = 28):</p> <p>grade 0: 2 (7%), grade 1: 8 (29%), grade 2: 11 (39%), grade 3: 77 (25%)</p> <p>After treatment (n = 28):</p> <p>grade 0: 7 (25%), grade 1: 8 (29%), grade 2: 10 (36%), grade 3: 3 (11%)</p> <p>colon</p> <p>Before treatment (n = 28):</p> <p>grade 0: 8 (29%), grade 1: 8 (29%), grade 2: 7 (25%), grade 3: 5 (18%)</p> <p>After treatment (n = 28):</p> <p>grade 0: 12 (43%), grade 1: 8 (29%), grade 2: 6 (21%), grade 3: 2 (7%)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Responsiveness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012351-tbl-0009"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Feasibility</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Feasibility Scoring</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012351-bbs2-0009" title="NainiBV , CortinaG . A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Human Pathology2012;43(12):2187‐96. ">Naini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naini and Cortina score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The scoring worksheet was easy to use, could be appropriately applied and was easily completed in less than 30 seconds for each patient </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Feasibility</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012351.pub2/full#CD012351-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012351.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012351-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012351-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012351-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD012351-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012351-note-0003">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012351-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012351\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012351\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012351\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012351\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012351\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WcPhDegp&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012351.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012351.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012351.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012351.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012351.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726419869"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012351.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726419873"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012351.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9335da459368',t:'MTc0MDcyNjQyMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 